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ABSTRACT
Small volume parenterals (SVP) are typically terminally
sterilized through autoclaving. This technigue works when
the containers are filled with a liguid. However, in the
case of sterile powders, autoclaving is not a viable method
nor is dry heat since most products can not withstand 2 50C
for a half hour. Thus gamma irradiation may be an
acceptable method to terminally sterilize this class of
product. One of the drawbacks of gamma irradiation is that
it will discolor glass which is currently the package
material of choice due to superior barrier properties and
relative inertness.
This paper explores the possibility of packaging one
product in a manner to accept gamma irradiation
sterilization. In doing so, the various reguirements of
SVP
'
s are reviewed. The package used was a polyethylene
terephthalate copolyester (PETG) vial that could withstand
the required level of radiation without any discernible
effects. The product was tested to determine what level of
radiation it could withstand. Finally, product was
irradiated and placed on stability to determine whether this
package and process are suitable. The PETG vial was found
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product on the market outweigh the risks associated with the
potential for microbial contamination.
In the case of dry powders, conventional heat
sterilization techniques will not work unless the product is
extremely heat tolerant. Dry powders, by nature, minimize
the risk that microbes will replicate since moisture is
generally required by them to sustain life. However, there
are currently no mathematical methods to fully evaluate the
SAL for aseptically filled products due to the low level of
sterility assurance and the number of adverse variables.
Thus media fill challenges and statistical sampling of
product must be employed.
Ionization sterilization by gamma irradiation is one
technique that may be used on dry-fill, small-volume
parenterals. However, in doing so there are a multitude of
issues that need to be reviewed to assure that the
sterilization requirements, product/package integrity and
reproducible validation results can be achieved. Factors
such as the bulk density of product, packing materials and
even presentation to the energy source can affect the final
outcome. The effects of radiation on the barrier properties
(WVTR, Gas Permeation, etc.) of the containers must also be
reviewed. Attention must also be given to any other effect
that the radiation may have on the container or product as
noted in Table 1.














One other area that presents a challenge is
depyrogenation. Pyrogens are proteins associated with
bacteria that are endotoxins, erythrogenic toxins or
exotoxins. These are characterized by being fever producing
3Parenteral Drug Association Microbial
Sub-Committee-
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and are commonly associated with such bacteria as
streptococcus and staphylococcus.4 Vials for parenterals
are typically exposed to 350C for not less than a half hour
to render them pyrogen free. This clearly would not be
suitable for most plastics. Work on radiation
depyrogenation is somewhat limited though initial studies
indicate that radiation may be
effective.5 If not,
determining a technique for this application will be
difficult, although acids, bases, oxidizers and washing are
other possible techniques that can be employed. However,
actual testing for depyrogenation will not be explored
within the scope of this paper.
In the studies detailed in this paper, a specific
product was chosen. Initial studies with this product were
useful in determining that the current container/closure
system was unsuitable due to discoloration of the glass
(Type I flint) . This phenomenon had been clearly
documented.6
However, it does allow the establishment of
baseline data.
4M. T. Parker, ed. , Toplev And Wilson's Principals Of
Bacteriology.Virology And Immunity, (Baltimore: Williams &
Wilkins, 1983), 185,231.
5C. T. Hudson and R. Nase, "Inactivation Of Endotoxins By
Ethylene Oxide Sterilization And Cobaltg0
Tr-r;grHationr "Deprocrenation, (Philadelphia: Parenteral Drug
Association 1985), 113-116.
6K. H. Sun and N. J. Kreidal, "Coloration Of Glass By
Radiation," The Glass Industry 33, no. 10 (1952): 511-516
4
The next study was with a polyethylene terephthalate
copolyester (PETG) vial. This resin was selected in that it
was initially felt that the product was not too moisture
sensitive. This resin also had the physical properties such
as clarity, ability to meet class VI in vivo and in vitro
studies, as defined by the United States Pharmacoepia/
National Formulary (USP/NF) , and has the ability to be
processed on existing filling equipment. This study
concluded that PETG was not suitable for this product since
it did not provide an adequate moisture barrier.
The purpose of this thesis will cover a number of
distinct issues. It will provide an insight into the
following package related issues one must explore when




Food and Drug Administration (FDA) Requirements
Finally, this paper will analyze the effects of 1 Mrad of
gamma-irradiation on a pharmaceutical product and the
suitability of a PETG vial for this product.
CHAPTER 2
LITERATURE REVIEW
Parenteral packaging is one of the most technically
intensive areas within the field. The reasons are twofold.
First is the need for sterility. In that injectable
pharmaceuticals bypass the alimentary system, lack of
sterility could lead to serious health risks without the aid
of the body's first line of defense. Thus the packaging
professional must have some familiarity with microbiology.
Second, the packaging professional must also be concerned
with issues involving chemistry. Again, any new compounds
that are added or formed by a reaction need to be reviewed
as to the impact on the product and patient. These studies
often need long term evaluation that is quite costly. Lack
of this review could lead to the FDA's classifying the
product as adulterated. Many of these products are also of
very low drug concentrations, thus loss of a small amount of
product into the packaging component could result in a
significant decrease in therapeutic activity.
CHAPTER 2.1
PACKAGING COMPONENTS
There are two distinctly different classifications of
sterile pharmaceutical packages. The first is large volume
parenterals (LVP) . These are usually plastic pouches or
large glass bottles that are typically used for infusion.
The second group is small volume parenterals (SVP) . This
group consists primarily of single dose (ampoules) ,
multi-
dose (vials) and ready for use (syringes) . Our focus in
this chapter will be an overview of those components used in
making a multi-dose container.
Multi-dose containers are composed of three major
components. They are the vial, stopper (closure) and seal.
The seal is generally not considered part of the primary
package since it does not come into direct contact with the
product. What it does provide is a tamper-evident seal,
protection from external contaminants relative to the site a
needle will penetrate and, paramount to the product,
sufficient compressive force to permit the stopper to seal
the vial. Thus the stopper and vial are the major
components we need to review.
Glass has been the container of choice for SVP's. It
provides the majority of properties needed to assure that
the products are in fact "safe, pure and
effective."
The
first property of glass that makes it well suited for
parenteral packaging is its superior barrier. Glass is
virtually impervious to water vapor and other gases. Thus
it provides the ultimate barrier provided that it's sealed
properly. The ampoule is often used for products that are
difficult to contain for this reason. Glass also lends
itself well to the rigors of parenteral processing. Its
ability to withstand high heats allows it to be
depyrogenated and sterilized before aseptic filling. Glass
also permits terminal sterilization through moist heat.
This is equivalent to an autoclave but requires that the
product be a liquid as the source for the internal moisture.
The tolerance of glass for a wide range of temperatures also
allows for other processes such as lypholization (freeze
drying) .
One other strong appeal of glass is its clarity.
Parenteral drugs go through a 100% inspection for
particulates. This process has been automated through
advanced electro-mechanical vision systems but is highly
dependent on the container's clarity for these systems to be
effective. These systems are also programmed to look for
other things such as glass defects.
Glass is by far not the optimal package for these
products. Glass defects do occur. Such defects can occur
during shipment, while the containers are being
8
processed/ filled or during manufacturing of the glass
container. The largest drawback of glass is its lack of
inertness. There are many different formulations of glass.
The components from these different formulations can leach
into the solutions, change the pH, react with the product
that, at times, can form crystals within the container.
Refer to Table 2 for some of the major components of glass.
In addition, the United States Pharmacopeia/ National
Formulary (USP/NF) has classified glass into four distinct
classes based on reactivity with definitive test methodology
to determine the class. They are as follows:
1. Type I (borosilicate)
This is the least reactive glass made primarily from boric
oxide and silicon dioxide. There are two sub-groups of
borosilicate glass. Type A has a lower thermal expansion
rate and is harder to form. This is more typically called
Pyrex glass. Type B is as chemically as inert as Type A but
has a higher expansion rate. Type B is primarily used in
pharmaceutical glassware. Sulfur dioxide treatment can be
used to further decrease reactivity though this is not
required in most cases. Type I glassware can either be
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2. Type II (de-alkalized soda lime!
This glass is usually treated with sulfur dioxide and
contains less migratory oxides than type III. It is more
sensitive to pH and can be adversely effected by the various
processes parenterals are put through. This and the other
soda lime glasses are molded.
3. Type III & NP glasses
These types of glasses are not used in sterile
pharmaceuticals due to their reactivity.8
A number of documents show the effects of type I
glass on pharmaceutical preparations. One example was the
precipitation of sodium fluosilicate in a multi-vitamin
solution.9 One area that has been of particular interest
has been the sorption of proteins and other compounds in
glass. This phenomenon affects drug products composed of
proteins in two ways. The first is loss of potency due to
adsorption. One drug that has been the subject of research
is insulin. One study, (Okamoto 1979) , documented this by
8Y. J.Wang and Y. W. Chien, Sterile Pharmaceutical
Packaging: Compatibility And Stability. (Philadelphia:
Parenteral Drug Association 1984) , 5-6.
9J. E. Tingstad et al. , "Stability Of Ascorbic Acid In A
Liquid Multivitamin Emulsion Containing Sodium Fluoride,"
Journal Of Pharmaceutical Science 52, (1963): 343.
11
showing losses could vary as high as 82%.
10 Thakker (1979)
also showed that non-biologies can also be lost. The study
he did on a quinolinol-secondary amine showed a 64%
loss.11
Brash (1991), performed a study that indicated that,
secondarily, some loss can be attributed to denaturing of
the proteins. He also goes on to suggest that HDPE and PET
plastics binding may be more related to surface smoothness
rather than chemical interactions. This factor will be of
greater concern as we move into highly potent recombinant
DNA products . 12
Plastic containers have a far greater number of
concerns. One concern is that gas and water vapor barriers
have not approached glass, to date. In general, when
plastic packaging is used for parenteral products, shelf
life is much less than the same product packaged in glass.
Product often must be protected by additional means such as
either freezing the product or protecting it by a secondary
barrier package such as a foil pouch. Plastics do have a
clear advantage in processing. While they cannot withstand
10H.Okamato et al. , "Adsorption Of Insulin To Infusion




1:LK. D. Thakker et al., "Loss Of A Hydrophobic Amine From
Solution By Adsorption Onto Container
Surfaces,"
Journal Of
Pharmaceutical Science 68, (1979): 93.
12J. L. Brash, Adsorption Of Proteins To Glass. High Density
Polyethylene And Polyester Films. (Hamilton: McMaster
University, 1991) .
12
conventional aseptic processing utilizing wet or dry heat
sterilizing techniques, they can be sterilized during
forming, filled using ultra filtration and then sealed.
This type of closed system processing would drastically
reduce manufacturing costs and may be able to meet the
10~6
SAL without terminal sterilization.
The major drawback has always been the selection of a
resin. Plastics are not homogeneous materials. There are a
number of additives used to improve processing, or added to
improve specific characteristics of the resin. Table 3
lists some of the major plastic additives and their roles.
The potential for leaching of a plastic or its additives
into product is extremely high and very well documented.
One such report Kim-Kang (1990) , identified 19 potential
extractables in a sample of PET. Six of these extractables
were identified in the pharmaceutical suspension contained
in the bottles
tested.13 In addition, Kampouris (1976),
identified two plasticizers from polyvinyl chloride (PVC)
that were extracted from the container into edible
oils.14
13H. Kim-Kang et al., "Methods For Predicting Migration To
Packaged
Pharmaceuticals." Journal Of Pharmaceutical
Sciences 79, no. 2 (1990): 120-123.
14E. M. Kampouris, "The Migration Of Plasticizer From
Polyvinyl Chloride Into Edible
Oils,"
Polymer Engineering








































































































































































































































































































































































































































These two plasticizers, di-2-ethylhexyl phthalate ester
(DEHP) and dibutyl phthalate (DBP) , came under much scrutiny
principally because of work done earlier by Jaeger and
Rubin (1970) that indicated that DEHP is not metabolized.16
This gave rise to many of the concerns about the use of PVC
for the packaging of liquid preparations for consumption.
There has also been a considerable amount of work done
on adsorption of drugs into plastics. Again, examples
abound in literature. Ilium and Bundgaard (1982) reported a
60% loss of diazepam and a 54% loss of nitroglycerin in PVC
bags in 8 hours.17
In addition to the sorption of drugs by the packaging
components, studies also concluded that some of the anti
microbial reagents used were also scavenged by plastics.
Bacteriostats are commonly used in multi-dose vials to
prevent contamination. Autian (1968) reported a 30% loss of
benzalkonium when stored in a polypropylene container at
accelerated temperatures. He also showed an 88% loss of
benzyl alcohol when stored in a polyethylene bottle under
16R. J. Jaeger and R. J Rubin, "Plasticizers from Plastic
Devices: Extraction, Metabolism, And Accumulation By
Biological
Systems," Science 170, (1970): 460.
17L. Ilium and H.Bundgaard, "Sorption Of Drugs By Plastic
Infusion




the same conditions. Methyl and propylparabens were also
susceptible to the same levels of adsorption.18
Permeation, however, has always been one of the largest
drawbacks in using plastics. This is not restricted to only
water vapor going in or out of the package. It also relates
to gases. There are many sterile pharmaceuticals that are
packaged under nitrogen because of oxygen sensitivity.
Permeation has forced the manufacturers of large volume
parenterals to overwrap plastic IV bottles in foil or other
high barrier materials to minimize moisture loss and
maintain a nitrogen blanket for oxygen sensitive products.
In addition, many LVPs have short shelf lives and/or are
frozen to slow down any chemical reactions.
The final component of a standard sterile
pharmaceutical package is the stopper. Stoppers also tend
to be one of the most problematic part of the package. It
has been mentioned that an ampoule is just about the
ultimate package as far as protecting a product is
concerned. However, today the majority of sterile packages
are vials. There are two major reasons for the increased
demand for vials. The first is that many customers would
rather buy multi-dose vials. This allows them to optimize
18J.Autian, "Interrelationship Of The Properties And Uses Of
Plastics For
Parenterals," Bulletin Of The Parenteral Drug
Association 22, (1968): 276.
16
their use of products where the dosage is patient dependent.
In addition, many people do not like opening ampoules out of
fear of cutting themselves on the glass. These concerns
have forced new advances in stopper development.
Stoppers have a number of functions and properties that
they must provide. The first, and probably most obvious, is
to provide a barrier. This means keeping product and
perhaps blanket gases such as nitrogen within the package
while excluding any reactive external agents such as
moisture or oxygen. Stoppers must also not react with the
product. Such reaction could range from adding extractables
to absorbing ingredients from the product.
The final specific reguirement for this type of closure
is its ability to be easily pierced by a needle. However,
once the needle is withdrawn, the stopper must be resilient
enough to fully reseal without leaving any fragments. This
property is known as coring. Stoppers are also physically
designed for their specifc use. Some examples of this would
be stoppers with legs to be used in conjunction with the
lypholization process or with multiple ports to be used for
infusion.
Processing of stoppers puts another burden on the
material. The stoppers must be sterilized before use. Heat
used during the sterilization process can adversely affect
the rubber. Thus, normally, much work must go into finding
17
the right balance between the heat the stopper can withstand
and the required sterility assurance level. Silicone is
also added to the stoppers to aid in the mechanical
stoppering of vials. The majority of today's pharmaceutical
stoppers are butyl or halogenated butyl rubber compounds.
Some companies have done work to include Teflon coatings





Micro-organisms are of dire concern within parenteral
preparations; thus material selections, formulations,
processing and actual drug administration must lend
themselves to assuring the product's sterility at the time
of use. Bacteria can grow in almost any environment. Some
bacteria grow under refrigerated conditions while others
require temperatures as high as 60C. Even limiting the
amount of oxygen or modifying pH will not prohibit certain
bacteria from growing.
Pharmaceutical manufacturers have two responsibilities
in assuring sterility- The first is to provide multi-dose
products with some form of preservative to prevent
contamination once a needle is inserted for the first dose.
The USP/NF under general tests and assays has provided a
list with limits of acceptable anti-microbials. In
addition, a test procedure has been provided within the same
section that permits testing each specific product to assure
the level of preservative is adequate. The second
responsibility is to assure that each and every parenteral
product is sterile after the manufacturing process. This is
the area with which we are most concerned.
19
The whole subject of assuring sterility is extremely
complicated. The level of contaminants in the raw
materials, the cleanliness of the processing area and
equipment, the process itself, and subsequent terminal
sterilization techniques all play a critical role in
determining the final sterility assurance level (SAL) of the
product. In the end, it is expected that the SAL of
10~6
is maintained.19 This means that there is a probability
that no more than 1\1,000,000 vials will be contaminated.
It is complicated to calculate this probability. The
easiest step is to develop the death rate of the specific
sterilization technigue to be employed. There is a linear
relationship that exists between a specific sterilization
technique, time, and the proportion of the contaminant
population that is destroyed within a given product. This
has been termed the D10 value (decimal reduction) which is
defined as the time (usually minutes) under a stated set of
exposure conditions reguired to reduce a surviving
homogeneous microbial population by a factor of 9 0% or 1 log
cycle.20 Thus the level of contaminants going into a
terminal sterilization process, or what is called the
19United States Pharmacopoeial Convention, United States
Pharmacopoeia XXII /National Formulary XVII. (Rockville: USP
Con., INC. 1990), 1706.
20A. Gennaro, ed., Remington's Pharmaceutical Science 17th
ed., (Easton:
Mack Publ. Comp., 1985), 1444.
20
bioburden, along with the D value determine the microbial
survivor probability.
The most common procedure used to destroy bacterium is
steam sterilization. This method uses a super-heated
(pressurized) steam usually in a chamber called an
autoclave. This method of sterilization can be used on
parts used in processing or product related packaging
components. It is also the most common terminal
sterilization technique used on liquid filled and sealed
parenterals. The liquid inside the vials provides the
pressurized steam required for this method of sterilization
to be effective. The minimal requirement is 15 minutes at a
minimum temperature of 121C, which is not only the
temperature in the chamber, but in every CC of liquid within
each container; thus calculations must include the starting
temperature of the product and the time it will take the
chamber to heat the product to the desired temperature.
This method terminates bacteria through coagulation of
protein.21 Much data exists to show the importance of
pressure in the process thus avoidance of air pockets is
critical to assure sterility. Other factors that must be
validated are the size of loads, the consistency of heat
21J. J. Perkins ,Principles And Methods Of Sterilization In
Health Sciences 2nd ed. , (Springfield: Thomas, 1969).
21
distribution within the chamber, the level of fill and head
space within a container.
Dry heat is another method used to sterilize products,
components and parts. However, it is less efficient than
steam sterilization, requiring greater heat or longer cycle
times. This method kills contaminants through an oxidation
process.22 It would take one hour at 170C to achieve the
level of sterilization of 15 minutes at 121C used in steam
sterilization. This method does have other advantages such
as depyrogenation, which will be covered in greater depth
later.
Gas sterilization is also used but has fallen from
favor due to both concerns for toxic and mutagenic residuals
and environmental issues due to the use of f luorocarbons.
Gas will not penetrate a sealed container, so it has limited
value in pharmaceutical preparations other then to sterilize
components. This method of sterilization requires control
of temperature, pressure, humidity and packaging parameters,
as does steam sterilization, but adds the intricacies of
controlling the gas. Ethylene Oxide is most commonly used
gas, and is often mixed with carbon dioxide or chlorof luoro
carbons to minimize the risk of explosions.
22J. J. Perkins .Principles And Methods Of Sterilization In
Health Sciences 2nd ed., (Springfield: Thomas, 1969).
22
Sterilization by ionizing radiation has been growing in
popularity by filling the void being left by the disuse of
gas sterilization. Radiation has many advantages such as
limited chemical reactivity, low to nil residue, and fewer
variables to control.23 The two major forms of ionizing
radiation are electron beam and gamma. Ultraviolet (UV)
radiation is used as well in the region of 253. 7nm.24
However, this has found little use in sterilizing product
since it has limited penetration. Any bacteria shaded by
dust particles, microscopic crevices, or packaging materials
will not be affected. It also reguires care to assure that
the bulbs are giving out the desired frequency as they age.
Thus the major uses of UV are limited to adding a germicidal
effect in aseptic areas and in some processing of water for
injection.
Gamma radiation is electromagnetic in nature, usually
using Cobalt-60 or Cesium-137 isotopes as a source.
Electron beam radiation utilizes an electron accelerator
such as a Van Der Graaff where electrons are accumulated
through cycling negatively charged electricity. The
electrons are then accelerated through a number of
23United States Pharmacopoeial Convention, United States
Pharmacopoeia XXII /National Formulary XVII. (Rockville: USP
Con., INC. 1990), 1707.
24A. Gennaro, ed. , Remington's Pharmaceutical Science 17th
ed., (Easton: Mack
Publ. Comp., 1985), 1450.
23
electromagnetic fields in a vacuum column. Electron beam
radiation can also be accomplished through a linear
accelerator that uses a cathode source for electrons. The
electrons are accelerated using microwaves. The major
difference in the ultimate effect of the two forms of
radiation is that gamma produces little detectable heat
while electron beam may increase temperatures in plastics up
to 10C and metals up to
40C.25
In selecting the proper dose of radiation, it is
critical to determine the amount needed to reach the desired
sterility assurance level while not adversely affecting the
product. The Association for the Advancement of Medical
Instrumentation (AAMI) Guideline for Gamma Radiation
Sterilization provides a number of methods for setting the
proper dose. These methods cover a number of contingencies
based on lot size and product experience.
The amount of testing needed before and after
irradiation is guite extensive, though it will vary
dependent on the method chosen. Testing relies on
incremental dose settings where both positive and negative
results are expected. The basic theory of all the testing
is to determine the dose needed to achieve a SAL of
10~2
.
This data is extrapolated out to the desired SAL level using
25M. Bakker and D. Eckroth, ed. , The Wiley Encyclopedia Of
Packaging Technology, (John Wiley & Son, Inc., 1986), 562.
24
industry accepted D10 data. However, since the D10 level is
based on a homogeneous population, the expected microbial
contaminants may vary in different products. The other
variable is the bioburden determination that uses various
sample sizes based on the frequency that a product is run.
Radiation sterilization, while perhaps easier to
control than other sterilization techniques, also requires
great care to assure reproducibility. The major factors
affecting dose absorbency are the activity and geometry of
the source, source to product distance, irradiation time and
product
geometry.26 In order to validate this process, the
first step is selection of dosimeters. There are eleven
types of dosimeters all with differing advantages and
disadvantages. Generally, more than one type is employed to
assure the accuracy of the data. The load configuration
must be established early since the way a product is packed
may have an impact on the absorbed dosage. Dosimeters are
usually placed throughout a load to assure the expected dose
levels are achieved. This procedure is termed dose mapping.
The movement of the carrier must also be controlled since
this affects irradiation time and proximity to the source.
26Parenteral Drug Association Microbial
Sub-Committee-




Science And Technology 42, no. 3S (1988): S6.
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There is much literature on the effects of radiation on
packaging materials. Glass, is unfortunately, affected by
radiation. The effect is limited to cosmetic discoloration
that varies with the dose, and fades with time and
temperature. However, this type of discoloration would not
be acceptable for a pharmaceutical product where consistency
is expected. Some work has been done indicating that both
lead and cerium oxide will inhibit discoloration. Cerium
oxide has an additional advantage of blocking UV rays that
may be harmful to some
products.27
However, the toxicity of
both heavy metals would make them unlikely candidates for
use in parenterals.
The effect of radiation on polymers is also well
documented. The chemical or physical properties of plastics
can change by chain scission, chemical degradation or cross
linking. Chain scission is the random rupturing of bonds
resulting in lowering the molecular weight of a resin.
Degradation can take place for a number of reasons.
The most common is oxidation. Antioxidants are commonly
added to inhibit the breakdown of the plastic over time.
One recent study tested oriented polypropylene and low
density polyethylene stabilized with different antioxidants.
Electron beam sterilization was used at 0 . 2 , 0.5, 1 and 2.5
27A. Ottoson, "What Makes Glass Change Color And What To Do
About
It," Ceramic Industry, (Sept. & Oct 1943).
26
Mrads. The results indicated that the antioxidants
decomposed forming new compounds.28
Cellulosics, polyvinylidene chloride, polyactals, and
f luorocarbons are examples of resins affected by radiation.
The major effects are discoloration and embrittlement.29
Embrittlement is usually attributed to cross linking which
increases tensile strength while decreasing impact
resistance. Generally, plastics with aromatic ring
structures absorb much of the energy thus tend to remain
stable. One study indicates that both polyvinylidene
fluoride and ethylene-co-tetraf luoroethylene may actually
exhibit improved tensile strength and thermal resistance.30
In addition, rubber is known to be drastically affected
by radiation in a similar fashion. Butyl rubber, the major
material used for pharmaceutical grade stoppers is known to
withstand only one Mrad. Fillers and antioxidants play a
key role in improving rubber's resistance to radiation. One
supplier has developed a butyl rubber formulation that is
stable up to 3 Mrads of gamma-ray irradiation. Thus, as
radiation sterilization is explored, it is critical that
28F. Bourges et al., "Effects Of Electron Beam Irradiation On
Commercial Polypropylene: Kinetic Study Of Antioxident
Degradation," Packaging Technology And Science 5, no. 4
(1992) : 197-204.
29M. Bakker and D. Eckroth, ed. , The Wiley Encyclopedia Of
Packaging Technology, (John Wiley & Son, Inc., 1986), 563.
30Ibid
27
attention be given to the selection of packaging materials
at the earliest phases.
Another method of sterilization that is often used is
filtration. Filtration removes but doesn't destroy
bacteria. In general, a 0.22 um non-shedding filter is
used. Pseudomonas diminuta are used to validate the system
since their size is approximately 0.3um based on a protocol
developed by the Health Industry Manufacturers
Association.31 The effectiveness of the filter requires
that the bioburden of the solution be monitored before
filtration. Other critical variables include filtering
pressure, flow rates and specific filter
characteristics.32
Some of the negative aspects of this form of sterilization
are low flow rates, limited use (solutions only) and
potential filter failure or shedding.
This technique is usually used in the processing of
parenterals and the water used to make them. It is used in
addition to other techniques in order to maintain a low
bioburden but it also removes extraneous particulates. The
USP/NF has set limits for particulates whereby the average
number of particulates is </= 10,000 of lOum in size or </=
31Health Industry Manufacturers Association,
"Microbiological Evaluation Of Filters For Sterilizing
Liquids," HIMA Document 4, no. 3 (1981).
32United States Pharmacopoeial Convention, United States
Pharmacopoeia XXII /National Formulary XVII. (Rockville: USP
Con., INC. 1990), 1708.
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1,000 of 25um in size per container.33 The inspections are
usually done by automated inspection systems that require a
high degree of package clarity to function properly.
Aseptic filling is also used to assure sterility- This
process requires that all parts and components are sterile
prior to being used. Vials may go through a dry heat cycle,
stoppers through an autoclave and the solution through
micro-filtration. This type of processing also requires
numerous plant controls to maintain sterility. The facility
usually has an inner core where the actual primary packaging
is being conducted. This area is maintained at a Class
1,000 level or higher. This means that there is only one
particle per 1000 cubic feet.
This level is maintained through careful selection of
building materials, meticulous maintenance, careful control
of individuals in the room, and special air handling systems
that literally filter the air. UV lights are at times used
as well as airlock or air shower systems at the entrance.
There are lower levels of room classifications surrounding
the inner core. The highest air pressure is always
maintained from the core out. This type of positive
pressure prevents microorganisms from entering the core.
33United States Pharmacopoeial Convention, United States
Pharmacopoeia XXII/National Formulary XVII
f (Rockville: USP
Con., INC. 1990), 1598.
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The air within these rooms is constantly sampled and tested.
Additionally, media fills are run periodically where culture
media is processed the same way that the product is. The
purpose is to prove that all controls are working properly -
The key to developing a fail-safe system for assuring
sterility is through the use of multi-tiered processes. In
addition, reducing the number of variables in each process
that can affect the outcome is also critical. There are
just too many variables that can go wrong with aseptic
filling as it's currently constituted. Thus great strides
are being made to limit these variables. One example of
this is form-fill-seal technology. Here the processing is
done without direct human intervention. The containers are
sterilized as they are being formed. The product is filled
through a filter and immediately sealed. This technique has
much promise though limited material selection has limited
its application. The materials (LDPE & PP) are not the best




Pyrogens are any of the microorganism related toxins
that cause fevers. These toxins are associated with the
outer most part of certain bacteria, usually gram negative.
These toxins are constantly being shed by the bacteria that
is why one gets a fever with certain illnesses. Therefore,
drugs for parenteral administration must be pyrogen free for
the well-being of the patients. Pyrogens can be present in
a sterilized product since they are the toxins and not
necessarily the bacteria. Thus treatments specific to the
toxins are required.
The most common method for rendering vials pyrogen free
is dry heat. The USP/NF standard for sterilization of 250C
for not less than 3 0 minutes was derived from a study done
by Welsh et
al.34 More recent studies indicate that heats
of 3 50C are required to depyrogenate.
35 Thus the toxins
require a greater temperature to deactivate than the
microbes themselves.
34H. Welsh et al., "The Thermostability Of Pyrogens And
Their Removal From
Penicillin," Journal Of The American
Pharmaceutical Association 34, (1945): 114.
35T. F. Elias et al., "A Laminar Flow Approach To In-Line
Vial
Sterilization," Bulletin Of The Parenteral Drug
Association 31, (1977): 33.
31
Glassware is typically produced at temperatures above
1500C.36 Thus directly after manufacturing it will be
pyrogen free. However, the reason the pharmaceutical
industry is concerned with glassware is that any moisture,
including that through condensation, along with packing and
handling could allow for contamination. Glassware is
typically washed, rinsed and then dried using sufficient
temperature to sterilize and depyrogenate it. Stoppers, on
the other hand, are typically washed and then rinsed with
water for injection. The stoppers are then typically
autoclaved at 121C and then dried at 105C. These cycles
are validated to assure conformance with appropriate
sterility and levels. Thus, while many plastics will not be
able to survive the 3 50C temperature needed to render glass
sterile and pyrogen free, other options may be available.
Some work has been done on various methods of chemical
deactivation of the toxins. One such method is hydrolysis
through the use of acids or bases. The studies on both
methods of depyrogenation indicate that they require heat to
be truly effective. They also indicate that acids and bases
affect pyrogens differently. One major study of the effects
of acid on the lipopolysaccharide (LPS) molecule shows that
acid cleaves off the biologically active Lipid A that
35J. Hanlon, Handbook Of Package Engineering, (New York:
McGraw-Hill Book Comp. 1971), 6-10.
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minimizes the pyrogenic effect of the toxin.37 Alkalines
work through saponification of the fatty acid portion of the
LPS molecule.38 It has not fully been established whether
this change in the molecule will detoxify it.
Oxidation through chemical means is another way to
neutralize the molecule. Hydrogen peroxide is one example.
One study showed that by pretreating with H202 and then
steam sterilizing, a pyrogenic 5% gelatin solution can be
rendered pyrogen
free.39
Thus, this method has tremendous
potential since low temperatures and concentrations of H202
are effective while also being relatively safe to use and
deactivate.40
Moist heat on its own has been found to be ineffective
at
depyrogenation.41
However, in conjunction with acids,
bases or oxidizers such as hydrogen peroxide, moist heat can
provide an effective way to depyrogenate at relatively low
temperatures. There has also been somewhat limited work
370. Luderitz et al., "Lipid A: Chemical Structure And
Biological Activity, "Bacterial Lipopolysaccharides,
(Chicago: University Of Chicago Press 1973).
38M. Niwa et al., "Alterations Of Physical, Chemical And
Biological Properties Of Endotoxin By Treatment With Mild
Alkali," Journal of Bacteriology 97, (1969): 1069.





40M. Gould And T. Novitsky, "Depyrogenation By Hydrogen
Peroxide," Deorogenation, (Philadelphia: Parenteral Drug
Association 1985), 91.
41A. Berger et al.,
"Pyrogens," Advances In Chemistry 16,
(Washington: American Chemical Society 1956), 168-197.
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done on other low heat methods such as gamma irradiation.
One study indicated a 88% drop in pyrogens when inoculated
with 4.5 Mrads of cobalt 60. 42 However, another study using
a higher dose of endotoxin, a different strain of bacteria
and other inoculated media was not able to show the same
efficacy.43
42K. Tsujii and S. Harrison, "Limulus Amebocyte lysate - A
Means To Monitor Inactivation Of Lipopolysaccharide,
"
Biological Applications Of The Horseshoe Crab (Limulidae) r
(New York: Alan R. Liss 1979), 353-378.
43C. T. Hudson and R. Nase, "Inactivation Of Endotoxins By
Ethylene Oxide Sterilization And Cobalt60
Irradiation




FOOD AND DRUG ADMINISTRATION REQUIREMENTS
One last area worth review is the Food and Drug
Administration's (FDA) guidelines for making these types of
changes. In the end, all the testing done on a container/
closure system must not only satisfy the specific company
but the FDA. The FDA has promulgated various guidelines to
assist manufacturers with the minimum requirements for
approval of a new primary package. The advantage of these
guidelines is that much of the requirements are based on the
evolution of knowledge based on the FDA's experience with
every pharmaceutical product on the market.
The first such guideline is that for stability studies.
The guideline starts out with the importance of evaluating
leachables even if the container meets USP/NF. The wall
thickness is also considered a critical parameter when doing
stability on plastic containers. It also provides the
guidelines for microbial quality- This includes microbial
challenge tests for multi-dose small volume parenterals
(SVP) .
The section specific to SVP's state that at a minimum
the strength, appearance, color, particulates, pH,
sterility, extractables and
degradation products, if
applicable, must be tested. In the case of reconstituted
35
products, the same tests must be performed with the
additions of the dispersibility and dissolution. All SVP's
with the exception of ampoules are to be stored and tested
in an upright and inverted mode to study the effects of the
closure system. The guidelines provide for terminally
sterilized product by requiring a maximum process parameter
with product stability data to support it. The upper and
lower limit of the sterilizing process and its corresponding
lethality range must be shown to be consistently effective.
The FDA has also developed a guideline for submitting
required documentation. The FDA considers the following
data to be critical when submitting a plastic parenteral
container:44
1. Name of Manufacturers
2. Type of Plastic
3. Composition, method of manufacture of the resin and
finished container, plus a full description of
analytical controls
4. Physical description (size, shape)
5. Light transmission, USP/NF
6. Tests, USP\NF
(a) Biological
44Center For Drugs And Biologies-Food And Drug
Administration,
" Guideline For Submitting Documentation For
Packaging For Human Drugs And
Biologies," (Rockville: Food





7. Vapor transmission test (if appropriate)
8. Toxicity studies not included in USP/NF
(a) Sub acute on extracts
(b) Cell culture studies




The FDA again notes that testing is critical on plastic
containers for parenterals in that there are a number of
ingredients added to the resin during processing. These
additives as well as the resins themselves have been found
to be reactive. Plastics also tend not to prevent migration
of moisture and gases as effectively as glass. It is
therefore critical that the plastic and its components be
fully characterized to assure that all shipments will be
made with the exact container tested.
The FDA goes on to state that even the labels used on
plastic containers must be tested since certain adhesives
have been found to migrate through the container wall. This






A moisture-labile dry parenteral was selected for use
in this study. The product was a semisynthetic,
broad-
spectrum cephalosporin antibiotic that requires
reconstitution prior to use. It is used both intravenously
and intramuscularly. The reason, as stated earlier, is that
dry products present a problem for pharmaceutical
manufacturers to terminally sterilize with conventional
techniques. In addition, it is hypothesized that many of
the concerns relative to extractables will be limited with
dry products. The product will hydrolyze, though the actual
rate needs to be established, which is why it is maintained
in powder form prior to use. The product is not able to
withstand the dry heat sterilization temperature of 250C
for 3 0 minutes. Thus gamma radiation was chosen as the
method to terminally sterilize it.
The package used as a control was a 10ml vial with a
2 0mm neck finish. The vial was molded from Type I flint
glass and sealed with a butyl rubber stopper and aluminum
crimp seal. The PETG
vial tested was also a 10ml vial with
a 2 0mm neck finish and average wall thickness of 1.2mm. The
resin used was Kodar PETG copolyester 6763. This vial was
also stoppered with the same butyl rubber compound and
aluminum crimp seal.
38
This resin was selected since polyester has shown to be
radiation stable. 4* m addition, the clarity and hardness
of the resin met production and marketing requirements. The
vial supplier, Nalge Company, provided 3 reports indicating
that this resin would meet USP/NF Biological Reactivity
Tests In-Vivo Class I-VI.46 This essentially means that
this resin should be suitable for use in SVP's provided
there aren't any reactions with the product, and the vial is
capable of providing adequate stability. Testing would also
have to include reconstituted products with the various
acceptable diluents for the time frames currently approved.
45W. Skiens, "Sterilizing Radiation Effects On Selected
Polymers.
"
(Richland: Pacific Northwest Laboratory n.d.)
52-53.
46T. Hogan, "Systemic Toxicity Test Of Centrifuge Bottles
(PETG. Polyethylene Terephthalate Copolyester) STS Test#
T85-152-1A (Rush: Sterilization Technical Services, Inc.
1985) ; T. Hogan, "Intracutaneous Test Of Centrifuge Bottles
(PETG, Polyethylene Terephthalate Copolyester^ STS Test#
T85-152-1B (Rush: Sterilization Technical Services, Inc.
1985) ; T. Hogan, "Muscle Implantation Study Centrifuge
Bottles (PETG. Polyethylene Terephthalate Copolyester) STS




PROCESSING AND TEST METHOD
The components were sterilized via the normal methods
for the specific component category. Stoppers were washed
with water for injection and then sterilized using moist
heat. The glassware was sterilized/depyrogenated using dry
heat. The PETG vials were sterilized using 2.5 Mrads. This
level was chosen based on AAMI 5.2.3.3 method 3 for single
lots, special orders, or
studies.47
The tests performed are in accordance with the USP/NF.
The moisture levels were determined by the titrimetric (Karl
Fischer) method. This is test method I (921) with an
acceptance range of 8.0 - 11. 0%.48 The assay was also done
by compendial method with an acceptance range of 90.0-115.0
of labeled claim. This test procedure nor product will be
cited in that it is considered confidential. However, the
data will be presented in order to evaluate the packaging
systems and potential for the use of radiation
sterilization.
47Gamma Radiation Sterilization Working Group, "Guidelines
For Gamma Radiation Sterilization AAMI ST32-R-3/91,
"
(Arlington: Association For The Advancement Of Medical
Instrumentation 1991) , 60.
48United States Pharmacopoeial Convention, United States






The first test performed was to establish the product's
tolerance for gamma irradiation by using dosage ranges from
0-10.0 Mrad. The test was performed on product packaged
through the standard processing cycle with current
components. The processing was standard aseptic procedures
whereby the components were pre-sterilized and
depyrogenated. The product was than filled in an aseptic
environment. The components used were Type I flint molded
glass vials with butyl rubber stoppers. Testing was done
immediately after the irradiation process to gauge the
initial impact of the terminal sterilization process.
Table 4.
Effects of Gamma Irradiation on the Product49
Radiation Dose Assay Product Appearance
0 Mrad 100% Off White
1.0 Mrad 101% Off White
2.5 Mrad 99% Slightly Darkened
5.0 Mrad 99% Slightly Darkened
10.0 Mrad 97% Moderately Darkened
49Internal Company Memo, 1981 (Confidential)
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This data indicated that 1.0 Mrad would be suitable for
this product in that it appeared not to have an effect.
Bioindicators containing spores of Bacillus pumilus were
used to test the effectiveness of 1.0 Mrad. This is
considered a bioindicator based on the organism's high
resistance to radiation.50 Tests were done at 0.5 and 1.0
Mrad with counts of 100 and 1000 spores, none of which were
positive.51 This would indicate that 1.0 Mrad would have a
sterilizing effect and that the actual SAL would need to be
computed based on the historical bioburden data from the
product. This data would also include the various species
to determine resistance to radiation sterilization. The
protocol used would be method 2, Protocol B Dose Setting for
ULTRA-CLEAN Good Manufacturing Practices. However, the SAL
will not be calculated within the scope of this paper though
it can be safely concluded that the sterility assurance will
be greatly increased.
The next test was designed to gauge the long term
effects of 1 Mrad on the product. Assay testing was
performed on the same Type I flint molded glass vial and
butyl rubber stopper. This product was again processed using
the standard aseptic technique outlined in the initial
50Gamma Radiation Sterilization Working Group, "Guidelines
For Gamma Radiation Sterilization AAMI ST32-R-3/91,
"
(Arlington: Association For The Advancement Of Medical
Instrumentation 1991), 70.
51Internal Company Memo, 1981 (Confidential) .
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study. This time the product was irradiated at 1 Mrad after
filling. This was used to establish a stability profile.
The numbers shown in Table 5 reflect the assay results that
indicated that the product could withstand 1 Mrad of gamma
irradiation.
The next set of studies was done to determine the
feasibility of using the PETG vial. These studies were
conducted with the same type of components and process of
the previous study- In this case, PETG vials were filled
using the same methodology used to prepare the glass vials.
The only exception was that the PETG vials were
pre-
sterilized with 2.5 Mrads of gamma radiation instead of
using dry heat. The glass and PETG vials were both filled
with the same lot of product. Assays and moisture analysis
were conducted on product both irradiated at 1 Mrad and
samples not terminally sterilized to act as a control. The
results are presented in Table 6.
The PETG vials did not meet the upper limit for
moisture of 11.0% under accelerated conditions. The
moisture studies were continued for three months at 3
7C-
85%RH. Table 7 provides the results of that testing. Again
at three months the product was continuing to increase
moisture levels. Thus PETG is considered unsuitable due to
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The data generated indicates that PETG would be
unsuitable due to moisture uptake. However, now that it has
been determined that the product requires a better moisture
barrier, a simplified technique can be employed in the
future. All plastics allow some moisture permeability.
Thus the first step in the future will be to establish the
water sorption characteristic of the product and water
vapor transmission rate of the packages to be tested.55
There are a number of new technologies on the horizon
that may make it possible to use plastic vials for this
product. One such technology is the use of chemical plasma
deposition techniques. In this technology, an organosilicon
monomer, helium, and oxygen are mixed in a chamber and
vaporized at a set pressure. Once vaporization is complete,
the vapor in the chamber is ignited forming a plasma that
catalyzes a Si02 coating onto the exterior of the vials.
Initial tests have concluded that the oxygen barrier can be
increased 10-fold and moisture barrier increased three
fold.56 The data presented in this paper do not have a
55M. Wang, "Prediction Of The Moisture Uptake By A Packaged
Moisture Sensitive Pharmaceutical Product Stored Under
Fluctuating Temperature And Humidity
Environments"
(M.S.
Thesis, Michigan State University, 1985) .
56Eastapac Company, "OLF Coating For Rigid Plastic
Packaging Technical
Brochure" (Concord: Eastapac Comp. 1991)
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sufficient number of data points to determine if this
increased barrier would be significant.
Some work has also been done on the effects of
radiation on Si02. This work concluded that radiation can
affect the coating though the dosage, 3 6Mrad, is much higher
than the product can tolerate.57 However, this would
warrant reviewing the impact of radiation sterilization on
the WVTR of coated vials.
In addition, a new amorphous polyolefin has been
developed which is characterized by a five member ring
structure in the polymer's main chain. This resin contains
no polar groups and has been found to meet USP/NF in-vivo
biological reactivity testing. The barrier properties that
have been reported with this resin have been exceptional.
However, the studies done on this material were not done
with the same methodologies; thus it is difficult to make a
comparison.58 Water vapor analysis can be done on this
amorphous polyolefin resin, Si02 coated PETG, and uncoated
PETG as a control. Testing should be done both irradiated
and non-ionized so that the impact of radiation can be
characterized. These materials can than be reviewed for
suitability with the
product used in this study or other
57R. Devine, "Radiation Induced Structural Changes In
Amorphous Si02: I. Point
Defects,"
Japanese Journal Of
Applied Physics 31, (1992): 4411-4421.
58Nippon Zeon Co. , Ltd. , "Amorphous Polyolefin Zeonex
Technical
Brochure," (Tokyo: Nippon Zeon Co., Ltd. 1992)
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similar products. However, it is crucial to determine the
barrier requirements of the product first. This way more
limited and less time-consuming testing can be completed
prior to long-term stability testing.
One other area for further study is in depyrogenation.
It became quite evident that if this vial were to work, much
effort would be needed in developing a new procedure for
depyrogenating plastic vials. Today most components are
rendered pyrogen free with either dry heat or washing with
water for injection. It became quite clear that both
ionizing techniques, as well as oxidizers, have potential.
In addition, there may be new methods through use of
recombinant DNA research that will allow protein scavengers
to neutralize the pyrogen and then be rinsed away easily.
However, the possibility that makes the most sense would
be depyrogenation through the heats used during
form/ fill/ seal processing. One study, provided by Nalge,
proved that 1 lot from three different tool set-ups (3
separate lots) were pyrogen
free.59 Nalge does use a
specialized process for the manufacturing and packaging of
components requiring this level of cleanliness. Challenge
testing will also be required to
prove that if pyrogens are
59D. Ventura, "LAL Validation
Program- Limulus Amebocyte
T.ys'ate Testing Of PETG Bottles STS Test Nos. T89-634, 635,
636," (Rush: Sterilization Technical Services, Inc. 1989).
49
present, the manufacturing process will destroy them. This
could be accomplished through an experiment where the resin
to be used is inoculated with a known level of pyrogens.
The level used would far exceed anything normally
encountered. The inoculated resin would than be subjected
to temperatures, time and pressures that would duplicate
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Use of Aseptic Processing and
Terminal Sterilization in the
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tor Human and Veterinary Use
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action: Proposed rule.
SUMMARY: The Food and Drug
Administration (FDA) is proposing to
amend the current good manufacturing
practice (CGMP) regulations for human
and veterinary drug products to require
manufacturers to use a terminal
sterilization process when preparing a
slerile drug product unless such a
process adversely affects the drug
product. The proposal would also
amend the regulations governing the
approval for marketing of new drugs
and antibiotics for human use and new
animal drugs to require applicants to
include in their marketing applications a
written justification with supporting
data when terminal sterilization is not
used to prepare a sterile drug product.
FDA believes these actions will provide
the highest possible assurance of
sterility for drug products intended to
be
sterile.
DATES: Written comments by December
10 1991. FDA proposes that any final
rule based on this proposal be effective
18 months after its date of publication in
Ihe Federal Register.
ADDRESSES: Written comments to the
Dockets Management Branch (HFA-
305), Food and Drug Administration, rm.
1-23, 12420 Parklawn Dr., Rockville, MD
20857.
FOR FURTHER INFORMATION CONTACT:
Marilyn L Watson, Center for Drug
Evaluation and Research (HFD-360).
Food and Drug Administration. 5600




There are two principal processes for
the preparation of sterile drug products.
Aseptic processing involves the filling or
assembly of presterilized drug products
under aseptic conditions into
presterilized containers. The drug
product and its container and closure
are sterilized separately, and the
sterilization meihods may differ
depending upon the physical
characteristics of the product and the
container and closure. For example.
liquid dosage forms are usually
sterilized through Filtration. Glass
containers are often sterilized using dry
heat; rubber closures are sterilized using
pressurized steam; and plastic
components may be sterilized using
ethylene oxide or radiation. The
sterilized drug product and sterilized
container and closure are then
assembled in a controlled environment.
The filled container is seldom subjected
to any further sterilization
process- but is
sealed and labeled as being sterile. The
many manipulations of the separately
sterilized components during the
assembly of the final drug product and
the absence of a final sterilization
process after the drug product has been
sealed in its final container limit the
degree of sterility assurance that can be
attained. Careful control and validation
of all operational phases of aseptic
processing is imperative to achieve the
highest possible degree of sterility
assurance. The failure to satisfactorily
process any component of the drug
product or Ihe product's container and
closure could result in contamination of
the other sterile components of the drug
product.
In contrast, terminal sterilization is a
process whereby a drug product, which
may or may not be presterilized, is filled
and sealed in a container and then
subjected to final sterilization. The
sterilization method is usually
autoclaving, a process that can virtually
eliminate the possibility of
contamination if properly validated and
carried out. Radiation is another method
of terminal sterilization. With terminal
sterilization of ihe final product, the
possibility of poststerilizarion
contamination of the drug product is
usually due to a breach of
container-
closure integrity.
The principal difference between
aseptic processing and terminal
sterilization of a drug product in the
degree of confidence regarding the
assurance of sterility is most notably
reflccled in the statistical probability of
the existence of a nonstenle unit in a lot
or batch. A properly conducted and
validated terminal sterilization process
will achieve a degree of sterility
assurance such that there will be less
than one chance in a million (10"") lh.it
viable microorganisms are present in
any final product container. In contrast.
current aseptic processing methods.
even when performed under optimal
conditions, can only be validated to
ensure that the contamination rate is no
greater than 1 contaminated unit per
1,000 (10*3) filled. In practical terms.
these statistical probabilities mean that.
for a drug product sterilized by a
properly controlled and validated
terminal sterilization process with an
uncompromised container-closure
system, there is virtually no chance of
microbiological contamination of the
drug product For a sterile drug product
prepared by aseptic processing under
validated and controlled conditions.
there is a substantial likelihood that at
least some drug products will be
microbiologically contaminated. In
addition, the sterilization method most
frequently used for the drug dosage form
in aseptic processing is filtration.
Because this physical process removes,
but does not inactivate, microorganisms,
it cannot prevent contamination of the
final drug product by viruses or other
viable biological components that
cannot be contained by a filtration
system.
Based on the above, the agency
concludes that terminal sterilization.
when properly performed, results in
drug products with a higher statistical
probability of sterility than those drug
products that are aseptically processed.
This conclusion is consistent with
explicit statements that terminal
sterilization is preferable and that
sterilization by filtration is the least
desirable method of sterilization that
appear in the regulations ofCanada, the
United Kingdom, Australia, the
European Pharmaceutical Inspection
Convention, and in the good
manufacturing practice guideline of the
European Economic Community. In
addition, an FDA analysis of recall data
from October 1981 to September 1991
demonstrates that virtu. illy all
"sterile"
drug products for human use that were
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subject to the 40 recalls for problems
involving sterility had been aseptically
processed. Some of the serious problems
that resulted from the marketing of some
of these products prior lo their recall
included a contaminated bone marrow
transplant resulting from a bacterial
contaminant in a heparin sodium
injection used in the transplant, serious
eye injuries resulting from contaminated
ophthalmic solutions, and a finding of




which have been subject to the seven
recalls between 1986 and 1991 du,3 lo
sterility problems involved products
which had been asceptically processed
rather than terminally sterilized. While
those recalled products which were
implicated in adverse reactions in
animals contained endotoxins, viable
microorganisms {Staphylococcus
hominis. Pseudomonas fluorescens, and
S. cohnii) have been isolated in two
products which were recently recalled.
The absence of reported adverse
reactions in animals as a result of viable
microbial contamination of injectable
products may be due to a number of
factors adverse actions may more
easily go undetecied in animals, and
they may go uninvestigated as a matter
of economics and/or lower emotional
concern.
In 1987, FDA issued its "Guideline on





greater degree of sterility assurance and
aseptic processing's greater risk of
possible contamination. However, the
guideline only provided information
on
acceptable practices and procedures for







products for human use to use terminal
sterilization whenever feasible.
II. Provisions of the Proposal
This proposed rule codifies the
agency's policy on the
preparation of
sterile drug products. The proposal
would amend the regulations regarding
CGMP (21 CFR part 211) and the
regulations governing the approval for
marketing of
new drugs and antibiotic
drugs for human use (21 CFR part 314)
and new animal drugs (21 CFR part 514)
to require manufacturers to use
terminal
sterilization when preparing sterile drug
products. The agency proposes to state
this policy by adding new 211.113(c)
and 211.186(b)(10) and by revising 21
CFR314.50(d)(l)(ii)and
514.1(b)(5)(vii)(6).
The proposal would permit
manufacturers to use aseptic processing
methods only if terminal sterilization
compromises product integrity. For
example, the manufacturer could justify
using aseptic processing by establishing
that the drug product is heat-labile, as in
the case of certain proteins and complex
biological products that are not stable
under conditions created by terminal
sterilization methods. In some cases, the
container closure system, for example, a
prefilled syringe, may offer a clear
benefit to patients but the system cannot
withstand terminal sterilization. To
justify aseptic processing for sterile drug
products, and applicant should present
scientific evidence with data showing
that unacceptable degradation of the
product or container occurs as a result
of terminal sterilization. This evidence
may be supplied as a result of direct
experimentation with the product in
question. These data may include, for
example, studies demonstrating
increased content of degradation
products, loss of container integrity, or
stability studies demonstrating other
adverse effects after terminal
sterilization. Such data could be
summarized in tabular form but should
include the methods used. Alternatively,
and applicant may submit articles from
the literature that provide adequate
justification in cases where the effects
of terminal sterilization are known. For
example, the sensitivity of some drug
substances to heal, and, hence,
autoclave processing, has already been
established and studies demonstrating
this sensitivity have been published.
Section 21l!ll3 of the CGMP.
regulations requires that manufacturers
establish and follow appropriate written
procedures designed to prevent
microbiological contamination of drug
products purporting to be sterile. FDA is
proposing to
amend 211.113 by adding
new paragraph (c)(1) to require sterile
products to be manufactured using
terminal sterilization unless such a
process will adversely affect the drug
product. When sterile products are not
sterilized by terminal sterilization, the
proposal would require manufacturers
to include in their written procedures an
explanation of the reasons why terminal
sterilization cannot be used. Data and
other information demonstrating that
terminal sterilization cannot be used
would be retained as part of the master
production and control records. The
agency proposes
to amend 211.186 by
adding
new paragraph (b)(10) to state
this requirement.
Under the proposal at revised
314.50(d|(l)(ii)
fo-
a new drug and
514.1(li)(5)(vii)(6> for a new animal
drug, an applicant would be required to
include in its marketing application a
writlen justification with supporting
documentation demonstrating why
terminal sterilization cannot be used.
Under the proposal, applicants of both
abbreviated new drug applications and
abbreviated new animal drug
applications would also be required lo
comply with these requirements.
For biological products, it is generally
understood lhat most products cannot
be terminally sterilized because they are
not stable under the stress caused by
the available methods of terminal
sterilization, and potency of the product
can be maintained only if sterility is
assured through aseptic processing
techniques. Therefore, the agency
concludes that this proposed rule would
impose a burden without any benefit
with respect to biological products by
requiring applicants to justify why
terminal sterilization cannot be used
when it has already been determined
lhat such a process is appropriate for
few, if any. biological products.
Accordingly, this propqsed.rule would
not apply to biological products. The
agency proposes to amend 211.113 of
the CGMP regulations by adding new
paragraph (c)(2) to state this exemption.
Failure to comply with these
requirements would result in a finding
that the drug product is adulterated
under section 501(a)(2)(E) of the Federal
Food. Drug, and Cosmetic Act (21 U.SC.
351(a)(2)(B)). It would also result in the
agency's refusal to approval a marketing
application for the product.
III. Proposed Effective
Date'
The agency proposes lhat any final
rule based on this proposal be effective
18 months after its date of publication in
the Federal Register. This effective date
reflects the time that FDA believes
applicants may need to adapt to the new
requirements. FDA specifically seeks
comment on whether this is an
appropriate effective date. During Ihe
18-month transition period, any
applicant who cannot use terminal
sterilization for preparing the sterile
drug product for which it is seeking
approval should include in its new drug,
new animal drug, abbreviated new drug.
or abbreviated new animal drug
application, or in an amendment to a
pending new drug, new animal drug.
abbreviated new drug, or abbreviated
new animal drug application,
justification with supporting dala
demonstrating why terminal sterilization
cannot be used. Any person holding an
approved application or abbreviated
application for a sterile new drug or new
animal drug product that -was not
prepared by terminal sterilization
should provide FDA with a justification
and supporting data demonstrating v.hy
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terminal sterilization cannot be used. or.
if the product can be terminally
sterilized, a supplemental application,
under 314.70fbj(2) or 514.8(a)(4) (21
CFR 314.70(b)(2)) or 514.8(a)(4))
providing for conversion to terminal
sterilization. The agen.y does not
anticipate appreciable delay in
reviewing a supplemental application to
provide for terminal sterilization. FDA
will make every effort to complete
review of these applications as quickly
as possible. The agency notes that
314.70(b) permits applicants to request
expedited review of a supplement for a
new drug for a change that requires
prior approval.
Before the effective date of the final
rule, any new drug, new animal drug.
abbreviated new drug, and abbreviated
new animal drug application under
review by FDA on or after the date of
publication of the final rule 4Jiat docs
not provide for the use of terminal
sterilization for preparing a sterile drug
product that can be terminally sterilized
may be approved if the application is
otherwise approvable and Ihe applicant
agrees to convert to terminal
sterilization by the effective date. On
and after the effective date of a rule,
FTJA will refuse to approve a new drug,
new animal drug, abbreviated new drug.
and abbreviated new animal drug
application if the applicant seeks
approval for a sterile product where
terminal sterilization is not used and the
applicant has not amended its
application to include a justification
with supporting documentation
demonstrating why terminal sterilization
cannot be used.
IV. Environmental Impact
The agency has determined under 21
CFR 25.24(a)(8) that this action is of a
type that does not individually or
cumulatively have a significant effect
on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
V. Economic Impact
The agency has examined the
economic impact of this proposed rule in
accordance with Executive Order 12291.
and has determined that the proposed
regulation does not constitute a major
rule. Furthermore, based on preliminary
data, the agency certifies that this
proposed rule will not have a significant
economic impact on a substantial
number of small entities, and. therefore.
does not require a regulatory flexibility
analysis under the Regulatory Flexibility
Act of 1960 (Pub, L. 96-354).
This proposed rule would require.
where appropriate, the use of a terminal
sterilization process in the preparation
of a sterile drug product in order to
decrease the risk of contamination that
may be associated with other methods
of sterilization. FDA estimates that the
total cost to firms of converting to
terminal sterilization would be $43
million. This figure of $43 rr;llion is a
combined cost for human drug
establishments and animal drug
establishments. The cost incurred by a
particular establishment will depend on
whether the firm needs to acquire new
equipment and/or make significant
renovations.
The proposed regulation will require
firms producing sterile products to incur
two types of costs: Capital costs for new
or additional equipment plus any
renovation needed for installing the
equipment; and costs for validation
testing of the new sterilization process.
which is needed for supplementing the
drug applications. After consulting with
several pharmaceutical companies who
recently converted their facilities to
handle the terminal sterilization of drug
products, FDA estimates that companies
would spend an average of $500,000 to
install an autoclave. If structural
changes to a plant for housing the new
equipment were necessary, FDA
estimates that an additional $250,000
would be incurred.
The companies will also need to
supplement the drug application where
there has been a change in the
sterilization process. The average
validation testing cost is estimated al
about $75,000. Because more than one
product can be validated in the same
cycle, the costs for validation testing for
one product is assumed to be the same
as the costs for validation testing of
numerous products.
There are approximately 221 human
drug manufacturing establishments
(affiliated with 158 firms) which
manufacture sterile products (small and
large volume parenterals and
ophthalmic products). The agency
estimates that approximately 40 percent
manufacture aseptically filled drug
products that could be produced via a
terminal sterilization process. Thus,
FDA estimates that approximately 88
human drug manufacturing
establishments would be affected by the
proposed rule. Based on FDA's
inspection experience, a little over
one-




terminal sterilization machinery and
trained personnel. Therefore, these 46
establishments will incur costs only to
run validation tests for those affected
sterile drug products not already
terminally sterilized. The remaining
40
establishments, have either limited or no
terminal sterilization capacity. These
establishments will need to purchase
capital equipment and run validation
tests. An estimated 22 of these 40
establishments may also need to
make
renovations to their plants.
The first set of 48 human drug
manufacturing establishments,
which
must only supplement drug applications
with validation tests, will incur one-time
costs of $3,600,000 (48 establishments X
$75,000 for validation tests) under the
proposed rule. The second group of
human drug manufacturing
establishments, comprised of the
roughly 18 establishments that will need
an increased capacity for terminally
sterilizing drug products, but not major
structural changes to the plant, will
incur one-time costs under the proposed
rule of about $10,350,000 (18
establishments x ($500,000 for
autoclave + $75,000 for validation
tests)). The final 22 establishments are
assumed to need structural changes to
their facilities in addition to new
autoclaves and validation tests. Thus.
these human drug manufacturers will
incur one-time estimated costs of
$18,150,000 (22 establishments X
($500,000 for autoclave + $250,000 for
renovation + $75,000 for validation
tests)).
In total, the estimated one-time cost
imposed on the 88 human drug
establishments is S32 million. On an
annual basis, assuming a 20-year
equipment lifetime and a 10 percent
interest rate, this amounts to about $3.8
million per year.
Similar average costs can be expected
to occur in the animal drug industry.
Officials of FDA's Center for Veterinary
Medicine estimate that there are roughly
40 establishments manufacturing sterile
animal drug products. However. 25 of
these establishments also manufacture
human drug products and costs
associated with terminal sterilization for
these establishments have been
included under the human drug
establishment estimate presented above
The remaining 15 sterile animal drug
manufacturing establishments are
expected to experience varying cost
impacts. The agency estimates that 10 of
the 15 establishments will incur initial
costs for purchasing an autoclave.
renovating or reconstructing, and
performing validation testing. The cost
to these 10 establishments totals
$8,250,000 (10 establishments X
(S500.000 for autoclave + $250,000 for
renovation + $75,000 for validation
tests)). The remaining 5 establishments
v. ill incur costs of $2,875,000 for
purchasing a
new or additional
autoclave and running validation lests
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(5 establishments X ($500,000 for
autoclave + $75,000 for validation
tests)). Thus, the total one-time impact
to these 15 animal drug establishments
is estimated to be $11,125,000. Or. an
annual basis these costs total $1.3
million per year.
Total annual costs amounting to $5
million (S3.8 million for human drugs
and $1.3 million for animal drugs) would
not have a substantial impact on the
manufacture of sterile drug products as
a whole. Nonetheless, while most larger
firms already have terminal sterilization
equipment in place and would
experience few significant cost impacts.
some smaller firms may not have
immediate access to the necessary
equipment and would either need to
borrow the capital fr.ir.ds or revise their
product lines. Although smaller
operations require smaller and less
expensive autoclaves, FDA is not
certain that it has identified all of the
costs that may be incurred by each type
of establishment. Thus, the agency
welcomes comments on the accuracy of
its estimated costs of compliance and on
the distribution of these impacts among
firms of different sizes.
In the international aiena, most
developed countries (Canada. Australia,
and the European Economic Community
Countries) already have guidelines or
regulations or guidelines in place which
specify terminal sterilization as the
preferable method of sterilization. Since
the majority of imported sterile finished
dosage form products come from those
countries which already prefer or
require terminal sterilization, no adverse
effect on imports is anticipated. In
addition, U.S. manufacturers which
terminally sterilize products for export
will experience increased demand and
reduced import restrictions, since these
products will meet the regulations of
other countries.
A more detailed copy of the agency's
assessment of the economic impact is on
file w ith the Dockets Management
Branch (address above). All public
comments regarding the cost of
switching from aseptic processing of a
sterile drug to terminal sterilization will
be reviewed and incorporated into the
agency's final economic assessment.
VI. Paperwork Reduction Act of 1980
Thi3 proposed rule contains
information collections which are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1980.
The title, description, and respondent
description of the information collection
are shown below with an estimate of the
annual reporting and recordkeeping
burden. Included in the estimate is the
lime for reviewing instructions,
searching existing data sources,
gathering and maintaining the data
needed, and completing and reviewing
the collection of information.
Title: Use ofAseptic Processing and
Terminal Sterilization In the Preparation
of Sterile Pharmaceuticals for Human
and Veterinary Use.
Description: This proposed rule woidd
require manufacturers applying for
marketing approval of a drug product to
describe the procedures that would be
taken to assure the drug product's
sterility. If the manufacturer seeks
approval for or has obtained approval of
a sterile drug product that was not
prepared using terminal sterilization, the
proposed rule would require the
manufacturer to justify in the marketing
application why terminal sterilization
was not appropriate. In addition, the
proposed rule would require a
manufacturer who does not use terminal
sterilization to prepare a sterile drug
product to keep in its files a justification
with supporting data demonstrating
whs-
terminal sterilization is not appropriate.
Description ofRespondents: Business.





























These estimates are an approximation
of the average time expected to be
necessary for a collection of
information. They are based on such
information as is available to FDA. The
agency seeks comment on these
estimates, particularly the
industries'
view of the number of firms and
products affected by the collections of
information contained in this proposed
rule.
The agency has submitted a copy of
this proposed rule to OMB for its review
of these information collections.
Interested persons are requested to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including
suggestions for reducing this burden, to
FDA's Dockets Management Branch
(address above), and to the Office of
Information and Regulatory Affairs,
OMB. rm. 3208. New Executive Office
Bldg., Washington, DC 20503, Attn: Desk
Officer for FDA.
VIII. Request for Comments
Interested persons may, on or before
December 10, 1991, submit to the
Dockets Management Branch (address
above), written comments regarding this
proposal. Two copies of any comments
are to be submitted, except that
individuals may submit one copy-
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the office
above between 9 a.m. and 4 p.m..
Monday through Friday.
List of Subjects
21 CFR Part 211
Drugs, Labeling, Laboratories.
Packaging and containers. Prescription
drugs. Reporting and recordkeeping
requirements. Warehouses.
21 CFR Pari 314
Administrative practice and
procedure. Confidential business
information. Drugs, Reporting and
recordkeeping requirements.
21 CFR Part 5U
Administrative practice and
procedure. Animal drugs. Confidential
business information. Reporting and
recordkeeping requirements.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
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1. The authority citalion for 21 CI'R
p,irt 211 continues to read as follows:
Authority: SffCS 201. 501. r.02. 505. 50b. 507.
512. 701. 70-1 of Ihe XiuY.il Food. Dm};, and
Cosmelic Acl (21 U.S.C. 321. 331. 352. 355. 350.
357. 3G0I). 371. 371}
2. Section 211 113 is amended by
adding new paragraph (c) lo read as
follows:
f 211.113 Control of microbiological
contamination.
(c)(1) Drug products purporting to be
sterile shall be sterilized by terminal
sterilization unless such process will
adversely affect those drug products. In
cases where terminal sterilization is
determined by the manufacturer to be
inappropriate, the written procedures
described in paragraph (b) of this
section shall include a justification for
this determination.
(2) Biological products for human use
are exempt from the requirements of
paragraph (c)(1) of this section.
3. Section 211.186 is amended by
adding new paragraph (b)(10) to read as
follows:




(10) In cases where terminal
sterilization is determined by the




PART 314-APPLICATIONS FOR FDA
APPROVAL TO MARKET A NEW DRUG
OR AN ANTIBIOTIC DRUG
4. The authority citation for 21 CFR
part 314 continues to read as follows:
Authority: Sees. 201. 301. 501. 502. 503. 505,
506. 507, 701. 700 of the Federal Food. Drug,
and Cosmelic Act (21 U.S C. 321, 331, 351. 352,
353, 355. 350, 357. 371. 376).
5. Section 314.50 is amended by
revising
paragraph (d)(l)(u) to read as
follows:






(ii) Drug product. A list of all
components used in the manufacture of
the drug product (regardless ofwhether
they appear in the drug product): and a
statement of the composition of the drug
product; a statement of the
specifications and analytical methods
for each component: the name and
address of each manufacturer of the
drug product; a description of the
manufacturing and packaging
procedures and in-process controls for
the drug product; such specifications
and analytical methods as are necessary
lo ensure the identity, strength, quality,
purity, and bioavailability of the drug
product, including, for example.
specifications relating to sterility.
dissolution rate, containers and closure
systems; and stability data with
proposed expiration dating. The
application may provide additionally for
the use of alternatives to meet any of
these requirements, including
alternative components, manufacturing
and packaging procedures, in-process
controls, methods, and specifications.
Reference to the current edition of the
U.S. Pharmacopeia and the National
Formulary may satisfy relevant
requirements in this paragraph. The
application for a sterile drug product
that is not sterilized by terminal
sterilization shall include a written
justification with supporting
documentation demonstrating why
terminal sterilization is not appropriate.
PART 514NEW ANIMAL DRUG
APPLICATIONS
8. The authority citation for 21 CFR
part 514 continues to read as follows:
Authority: Sees. 501, 502, 512, 701, 706, 801
of the Federal Food. Drug, and Cosmetic Act
(21 U.S.C. 351, 352. 360b. 371. 376. 381).
7. Section 514.1 is amended by










() If the article is one that is
represented to be sterile, the same
information wilh regard to the
manufacturing, processing, packaging.
and the collection of samples of the drug
should be given for sterility controls.
Include the standards used for
acceptance of each lot of the finished
drug. If the article is not sterilized by
terminal sterilization, a written
justification with supporting
documentation demonstrating why
terminal sterilization is not appropriate
shall be provided.
Dated: May 15, 1991.
David A. Kessler,
CommissionerofFoodandDrugs.




44 CFR Parts 65 and 72
RIN 3067AB 66
National Flood Insurance Program;
Identification and Mapping ot Special
Flood Hazard Areas and Procedures






SUMMARY: This proposed rule would
revise the National Flood Insurance
Program (NFfP) regulations on
identification and mapping of special
hazard areas. The proposed rule would
initiate a fee requirement for map
revisions, similar to the current fee
procedures for conditional Letters of
Map Amendment (CLOMAs) and
conditional Letters ofMap Revision
(CLOMRs), by establishing
administrative and cost recovery
procedures for the review and issuance
of Letters ofMc.p Revision (LOMRs) and
map revisions requested to reflect
changed flood hazards. This action is
being undertaken to reduce expenses to
the National Flood Insurance Program
(NFIP) and will contribute to
maintaining the NFIP as self-supporting.
Also, the proposed rule deletes the
listing of initial fees and references to
pre-authorized spending limits set forth
in the current regulations at 72.3 and
72.4 and substitutes language which
provides for publication of fees and pre-
authorized spending limits in a separate
listing. This action is being undertaken
to permit FEMA to adjust fees to
accommodate the increased rates FEMA
must pay for these activities and to
eliminate the necessity of undertaking
formal rulemaking solely for the purpose
of adjusting fees. The listing of fees
proposed to be effective through
September 30, 1992, is published as a
notice elsewhere in this Federal Register
and will be finalized with the final rule.
Under this proposed rule, the fees would
be adjusted annually to provide for
changes in the prevailing private sector
labor rale upon which the fees are
predicated. Revised fees will be
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7500West Henrietta Rd. Rush. New Yortc 14543 (716)533-1672
STS Test No. T85-1582-1A
TEST SUMMARY
Systemic Toxicity Test (PLT-1.0 - 2.0)
Test Article: Centrifuge Bottles
The test article (Centrifuge Bottle) submitted for analysis was extracted in a
sodium chloride solution, a 1:20 solution of alcohol in sodium chloride,
polyethylene glycol *00 and cottonseed oil. All extracts were subjected to 70C
for 2*.0 hours. Negative controls were prepared by subjecting the vehicle only
to the extraction procedure. Five (5) albino mice (TAC: (CFW)fBR) were
injected Gv) with the sodium chloride extract at a dosage of 50 ml/kg. Five mice
were injected (iv) with the 1:20 alcohol in sodium chloride extract at a dosage of
50 ml/kg. Five (5) mice were injected (ip) with the polyethylene glycol *00
extract at a dosage of 10 g/kg, and five (5) mice were injected (ip) with the
cottonseed oil extract at a dosage of 50 ml/kg. All mice were injected at a rate
of 0.1 ml/second. Control groups consisting of five (5) mice/group were injected
IV or IP with the appropriate vehicle. The animals were observed for signs of
toxicity immediately after injection and at *, 2*, *8 and 72 hours
post injection.
All observations of the mice were normal. The test sample (Centrifuge Bottle)
meets the requirements of the Systemic Toxicity Test.






















Division of Sybron Corp.
75 Panorama Creek Drive
PO Box 365, Rochester, NY 1*602
Linda Kover
Verbal/Linda Kover
Sterilization Technical Services, Inc.
7500 West Henrietta Road
Rush, New York 1*5*3
Toxicology Test No. T85-1582-1A
N/A
PLT-1.0; PLT-2.0
June 11, 1985 through June 1*, 1985
Thomas M. Hogan
STS has received and evaluated the following sample
submitted on the date indicated:
Centrifuge Bottles
Received: May 30, 1985
This study is designed to evaluate acute systemic toxicity
of a polymeric material extract following a single
intravenous or intraperitoneal injection into mice.
Previously unused albino mice (17-23 g) were injected
intravenously or intraperitoneally with extracts. The
mouse was chosen for this study because it has
historically been used to evaluate biomaterial extracts
and is the test system suggested by the US Pharmacopeia
and the National Formulary (Volume XXI and XVI
combined).










60 cm 2 of the test material was added to 20 ml of sodium
chloride solution. 60 cm 2 of the test material was added
to 20 ml of a 1:20 alcohol in sodium chloride solution. 60
cnr>2
of the test material was added to 20 ml of
cottonseed oil, and 60
crn2 of the test material was added
to 20 ml of polyethylene glycol *00. Each test sample
extract was subjected to 70C for 2*.0 hours. Blanks of
each vehicle were subjected to the same extraction
procedure.
Previously unused, healthy, albino mice (TAC: (CFW)fBR)
were injected IV for both the saline extract and the 1:20
alcohol in sodium chloride extract with 50 ml of
extract/kg of body weight at an injection rate of 0.1
ml/second. The polyethylene glycol *00 extract was
injected IP with 10 g of extract/kg of body weight at an
injection rate of 0.1 ml /second, and the cottonseed oil
extract was injected IP with 50 ml of extract/kg of body
weight at an injection rate of 0.1 ml/second. Control
groups consisting of 5 mice/group were injected with the
appropriate vehicle. The animals were observed for signs
of toxicity immediately after injection, then at *, 2*, *8
and 72 hours post injection.
The results of this study are presented in Table I of this
report. There were no circumstances during the course of
this study that affected the quality or integrity of the
data obtained.
There were no signs of toxicity observed in animals
treated with the test material or the blank. All
observations of the mice were normal, therefore, the test
material (Centrifuge Bottle) meets the requirements of
the Systemic Toxicity Test.
All raw data, documentation, protocols and final reports
generated for this study will be retained in the archives at
Sterilization Technical Services, Inc., 7500 West
Henrietta Road, Rush, New York 1*5*3.
STS Standard Operating Procedures were followed. No
other Quality Assurance was necessary.
1) U.S. Pharmacopeia and the National Formulary
(Volume XXI and XVI combined)
2) Sterilization Technical Services, SOP No. PLT-1.0
"Systemic Toxicity Test (Intravenous)".
3) Sterilization Technical Services, SOP No. PLT-2.0
"Systemic Toxicity Test (Intraperitoneal)".
STSTestNo.T85-1582-lA Page 5
Study Personnel: Thomas M. Hogan,
Scott Anderson,
Andrea Rogers,
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STS Test No. T85-1582-1A Attachment I








difficult or labored breathing; gasping
a transient cessation of breathing following a
forced respiration
C) Cyanosis: bluish appearence of tail, mouth, foot pads
D) Tachypnea: quick and usually shallow respiration
E) Nostril discharges: red or colorless
Motor Activities
A) Decrease or increase in spontaneous motor activities, curiosity,
preening or locomotions
animal appears drowsy, but can be aroused by
prodding and resumes normal activities
inability to control and coordinate movement
with no spasticity or rigidity
immobile and rests on belly







A) Clonic convulsion: convulsive alternating and relaxation of
muscles
B) Tonic convulsion: persistent contraction of muscles, attended by
rigid extension of hind limbs
C) Tonic-clonic
convulsion: both may appear consecutively
Ocular Signs
A) Lacrimation: excessive tearing, clear or colored
Salivation
A) Excessive secretion of saliva: hair around
mouth becomes wet
STS Test No. T85-1582-1A Attachment I (Cont.)
SYSTEMIC TOXICITY TEST (PLT-1.0 - 2.0)
Grading Criteria
VI. Piloerection
A) Contraction of erectile tissue of hair follicles resulting in rough
hair
VII. Gastrointestinal Signs
A) solid, dried, and scant
B) loss of fluid, watery stool
VIII. Skin Reaction
A) Edema: swelling of tissue filled with fluid
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Division of Sybron Corporation
75 Panorama Creek Drive
PO Box 365, Rochester, NY 14602
Attn: Linda Kover
Prepared By:
Sterilization Technical Services, Inc.
7500 West Henrietta Road
Rush, New York 14543
Approved By:
Thomas M. Hoat>^
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STS Test No. T85-1582-1B
TEST SUMMARY
Intracutaneous Test (PLT-3.0)
Test Article: Centrifuge Bottles
The test article (Centrifuge Bottle) submitted for analysis was extracted in
sodium chloride solution, a 1:20 solution of alcohol in sodium chloride, in
polyethylene glycol 400, and in cottonseed oil using the appropriate extraction
procedure. All extractions were subjected to 70C for 24.0 hours. Negative
controls were prepared by subjecting the vehicle only to the extraction
procedure. Four (4) healthy, thin-skinned albino rabbits not previously used for
any test were used in this stud/. Each of two (2) rabbits were injected with 0.2
ml of one extract at ten sites cephalically, another extract was injected in the
same manner caudally. This procedure was repeated using the remaining two
rabbits and two extracts (all sample extracts were injected on the right side of
the spinal column of each animal). Similarly, 0.2 ml of each blank extract was
injected at 5 sites on the left side of the spinal column of each animal. The
animals were observed at 24, 48 and 72 hours after injection for gross evidence
of tissue reaction such as erythema, edema and eschar. All observations of the
rabbits were normal, therefore, the test sample (Centrifuge Bottle) meets the
requirements of the Intracutaneous Test.






















Division of Sybron Corporation
75 Panorama Creek Drive
PO Box 365, Rochester, NY 14602
Linda Kover
Verbal/Linda Kover
Sterilization Technical Services, Inc.
7500 West Henrietta Road
Rush, New York 14543
Toxicology Test No. T85-1582-1B
N/A
PLT-3.0
June 12, 1985 through June 15, 1985
Thomas M. Hogan
STS has received and evaluated the following samples
submitted on the date indicated:
Centrifuge Bottles
Received: 5/30/85
This study is designed to evaluate the extracts of
polymeric material in rabbits for toxicity of leachable
components.
Healthy, thin-skinned albino rabbits (Hra: (NZW)SPF) not
previously used for any test, were used in this study. This
test system is recommended by the U.5. Pharmacopeia
and the National Formulary (Volume XXI and XVI
combined).




60 cm2 of the test sample (Centrifuge Bottle) was added
to 20 mis of each of four (4) extracts (sodium chloride
solution, 1:20 solution of alcohol in sodium chloride,
polyethylene glycol 400, and cottonseed oil). All extracts
were subjected to 70C for 24.0 hours. Blanks of each
vehicle were subjected to the same extraction procedure.
An area around the spinal column of each rabbit was
shaved prior to the initiation of the study. Each of two
(2) rabbits were injected intracutaneously with 0.2 ml of
one extract at ten sites cephalically, another extract was
injected in the. same manner caudally. All sample
extracts were injected on the right side of the spinal
column of each animal. Similarly, 0.2 ml of each blank
was injected intracutaneously at 5 sites on the left side of
the spinal column of each animal. This procedure was
repeated using the remaining two (2) rabbits and two (2)
extracts.
The injected sites were examined at 24, 48 and 72 hours
after injection for gross evidence of tissue reaction such
as erythema, edema and eschar. The observations were
rated on a numerical scale for the extract of the sample
and for the blank, respectively, using the following
scoring system:
Table I: Evaluation of Skin Reactions
Erythema and Eschar Formation
No erythema
Very slight erythema (barely perceptible)
Well defined erythema
Moderate to severe erythema
Severe erythema (beet redness to slight








Very slight edema (barely perceptible) 1
Slight edema (edges of area well defined
by definite raising) 2
Moderate to severe edema (raised approximately 1 mm) 3
Severe edema (raise more than 1 mm and
extending beyond the area of exposure) 4






All observations of intracutaneous injection sites of both
the test sample extracts and blanks were normal at the
24, 48 and 72 hour observation points. The test article
(Centrifuge Bottle) meets the requirements of the
Intracutaneous Test.
All raw data, documentation, protocols and final reports
generated for this study will be retained in the archives at
Sterilization Technical Services, Inc., 7500 West
Henrietta Road, Rush, New York 14543.
STS Standard Operating Procedures were followed.
other Quality Assurance was necessary.
No
1) U.S. Pharmacopeia and the National Formulary (Volume
XXI and XVI combined)
2) Sterilization Technical Services, Inc. SOP No. PLT-3.0
"Intracutaneous Test".
Study Personnel: Thomas M. Hogan,
Scott Anderson,
Andrea Rogers,























48 hour 72 hour
Sample Blank Sample Blank Sample Blank
Sodium Chloride 0/0 0/0 0/0 0/0 0/0 0/0
Polyethylene 0/0 0/0 0/0 0/0 0/0 0/0
Glycol 400
Sodium Chloride 0/0 0/0 0/0 0/0 0/0 0/0
Polyethylene 0/0 0/0 0/0 0/0 0/0 0/0
Glycol 400
1:20 Alcohol 0/0 0/0 0/0 0/0 0/0 0/0
in Sodium Chloride
Cottonseed Oil 0/0 0/0 0/0 0/0 0/0 0/0
1:20 Alcohol 0/0 0/0 0/0 0/0 0/0 0/0
In Sodium Chloride
Cottonseed Oil 0/0 0/0 0/0 0/0 0/0 0/0
* See Table I for Evaluation of Skin Reactions
;por
_
. . Erythema and Eschar Formation Value
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P.O. Box 365
Rochester, New York 14602
Attention: Linda Kover
Prepared By:
Sterilization Technical Services, Inc.
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STS Report No. T85-1582-1C
TEST SUMMARY
Muscle Implantation Study (PLT-4.0)
Test Article: Centrifuge Bottles
Two (2) healthy, adult New Zealand white rabbits (Hra: (NZW)SPF) weighing not
less than 2.5 kg, and whose paravertebral muscles were sufficiently large in size
were used. Four (4) USP Negative Control Plastic Strips were loaded into a
trocar/hypodermic needle assembly, wrapped and sterilized. An area around the
spinal column of both rabbits was shaved prior to the initiation of the study.
Both rabbits were anesthetized using
Rompun^ 5 mg/kg and
Ketaset^ 44 mg/kg.
Four (4) 10x1 mm strips of the test material were implanted using a
trocar/hypodermic needle assembly into the paravertebral muscles on the right
side of the spine of each of two rabbits. Two (2) negative controls were
implanted in the left paravertebral muscles on the opposite side of the spinal
column of both rabbits. The incisions were closed using Michel clips and the
animals returned to their respective cages. After four (4) days the rabbits were
sacrificed using
T-61^ Euthanasia Solution. The tissue surrounding the samples
and negative controls were examined macroscopically. In addition to the
macroscopic examination, histopathology was performed on each implant site
and the surrounding tissue. The results indicate very slight toxic responses
observed in the tissue surrounding the test samples. The tissue reaction of the
test material implant sites were not significantly different from the tissue
reaction of the negative control strips. The sample (Centrifuge Bottle) meets
the requirements of the Muscle Implantation Study.























Division of Sybron Corporation
75 Panorama Creek Drive
P.O. Box 365
Rochester, New York 14602
Linda Kover
Verbal/Linda Kover
Sterilization Technical Services, Inc.
7500 West Henrietta Road
Rush, New York 14543
Toxicology Test No. T85-1582-1C
N/A
PLT-4.0
June 10, 1985 to June 14, 1985
Thomas M. Hogan
STS has received and evaluated the following samples
submitted on the date indicated:
Centrifuge Bottles
Received: 05/30/85
This study is designed to evaluate the toxicity of
leachable components of a polymeric material following a
four (4) day muscle implant.
Two (2) healthy, adult New Zealand white rabbits (Hra:
(NZW)SPF) weighing not less than 2.5 kg, and with
paravertebral muscles sufficient in size for implantation,
were used in this study. The animals are anesthetized
with a commonly used anesthetic agent to a degree deep
enough to prevent muscular twitching. This test system is
recommended by the US Pharmacopeia and the National
Formulary (Volume XXI and XVI combined).
STS Test No. T85-1582-1C Page 4
Methods: The area around the spinal column of two rabbits was
shaved prior to the start of the study. The test was
performed in a clean surgical area where aseptic
conditions were maintained throughout the implant
procedure.
After the rabbits were anesthetized, four (4) 10x1 mm
strips of the test sample (Centrifuge Bottle) were
implanted using a trocar/hypodermic needle assembly into
the paravertebral muscles on the right side of the spine of
each of two rabbits. The test sample strips were as
smooth as possible to avoid additional mechanical trauma
upon implantation. Each sample was implanted 2.5 to 5
cm from the midline and parallel to the spinal column,
and approximately 2.5 cm apart from each other. Using
the same procedure, USP negative control strips were
implanted in the opposite muscle of each rabbit using a
trocar/hypodermic needle assembly. The incisions were
closed using Michel clips and rabbits were returned to
their respective cages.
After (4) days the rabbits were sacrificed using
T-61R
Euthanasia Solution. The tissue surrounding the samples,
as well as that surrounding the control strips, was
examined macroscopically for hemorrhaging,
encapsulation and any tissue reaction. The tissue was










= a moderate reaction
= a marked reaction
= a questionable reaction
In addition to the macroscopic examination,
histopathology was performed on each implant site and
the surrounding tissue.
The results of this study are presented in Tables I and II of
this report. There were no other circumstances during
the course of this study that affected the quality or
integrity of the data obtained.
The histopathology results indicate a very slight toxic
reaction of the muscle to the test sample and the
negative control strips. The tissue reaction at the test
material implant sites is not significantly different from
the tissue reaction of the negative control strips.







The histopathologist firmly believes the tissue reaction at
the test and negative control implant sites is due to, and
indicative of, the natural healing process brought about by
the trauma of implanting the test and control materials.
In addition, one would always expect a certain amount of
tissue reaction simply due to the response of the animal,
and it's immune system to a foreign body.
In conclusion, when the macroscopic results, the
histopathological or microscopic results, and the
judgement and knowledge of the histopathologist are
considered, the test sample analyzed in this test did not
cause a reaction significantly different from the reaction
of the tissue to the negative controls.
The test sample (Centrifuge Bottle) meets the
requirements of the Muscle Implantation Test.
All raw data, documentation, protocols, interim and final
reports will be retained in the archives at Sterilization
Technical Services, Inc., 7500 West Henrietta Road, Rush,
New York 14543.
STS Standard Operating Procedures were followed. No
other Quality Assurance was necessary.
1) US Pharmacopeia and the National Formulary
(Volume XXI and XVI combined).


















Rabbit No. Sex Samples Negative Controls
1 2 3 4 5 6
50346 F 0 0 0 0 0 0
50347 F 0 0 1 0 0 0
Explanation of Scoring System:
0 = non-reactive
0 = slight reaction
2 = moderate reaction
3 = marked reaction
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STS Test No. T85-1582-1C
Attachment I
PLT-4.0 MUSCLE IMPLANTATION TEST
HISTOLOGY SCORING PROCEDURE
A) Necrosis G) Giant cells
B) Inflammation H) Foreign body debris
C) Polymorphonuclear 1 ) Fibroplasia
leukocytes 3) Fibrosis
D) Macrophages K) Fatty infiltration
E) Lymphocytes L) Relative size of involvement
F) Plasma cells
A) Grade each of the above parameters according to the following scoring
system:
0 = item not present
1 = item occasionally present
2 = item present to a mild degree
3 = item present to a moderate degree
4 = item present to a marked degree
Total scores
B) Determine Overall Toxicity
Rating:*
Total from part A
0 = nontoxic 0-6
1 = very slight toxic reaction 7-18
2 = mild toxic reaction 19-30
3 = moderate toxic reaction 31-42
4 = marked toxic reaction 43-48
?The overall rating may be weighted
at the discretion of the
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STS Test Nos. T89-634, 635, 636
MALGE COMPANY
LAL Validation Program
LIbuIus Amebocyte Lysate Testing of
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Attn: Jean VanBuren
Prepared By:
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STS Test Nos. T89-634, 635, 636
NALGE COMPANY
TEST SUMMARY
Test Articles: PETG Bottles (125 ml, 500 ml and 1000 ml capacity), Lot
Nos. 257019D8, 074250D8 and 551636C8, respectively
Test Description: The LAL Test was conducted on extracts obtained from
each of three separate lots of the test sample. The
extracts were prepared by filling each sample with
sterile, pyrogen-free water. LAL
inhibition/enhancement
testing was also conducted on these
extracts to
determine the effects, if any, on the lysate gel
reaction.
A USP In Vivo Pyrogen Test was also conducted, in
parallel, on each lot of the test sample.
These
extracts were prepared by filling each sample with
sterile, pyrogen-free 0.9% sodium
chloride solution.
The extract was injected intravenously into the
marginal ear vein of each of three (3) rabbits at a
dose of 10 ml/kg. Once an hour for three (3) hours,
the body temperature of each rabbit was
determined.
The individual maximum temperature rise and combined
maximum temperature rise was calculated.
Results- Three lots of PETG Bottles (Lot Nos. 257019D8 (125
'
nils), 074250D8 (500 mis) and 551636C8, (1000 mis))
were
determined to be free of pyrogens by the LAL Pyrogen
test at a sensitivity of 0.25 EU/ml . The test extracts
did not cause inhibition or enhancement of the LAL clot
development.
All samples extracts for the USP Rabbit Pyrogen
Test
met USP requirements. Individual maximum
temperature
rise was less than 0.6C. Combined maximum temperature
rise was less than 1.4C.
Conclusions: The LAL test was shown to be
as sensitive as the USP
Rabbit Pyrogen Test.
The results of the tests conducted, and
reported here,
indicate that the LAL test is reliable and a
valid test
for evaluating this product for pyrogens.
STS Test Nos. T89-634, 635, 636 Page 3
Sponsor: Nalge Company
75 Panorama Creek Drive




Test Facility: Sterilization Technical Services, Inc.
7500 West Henrietta Road
P. 0. Box 349
Rush, New York 14543
Test Facility
Reference Nos.: GLP Study No. GLP-1989-001
Rabbit Pyrogen: T89-121, 123, 125
Standard Operating
Procedure Nos. : PYT-1.0 USP In Vivo Pyrogen Test
PYT-2.42 Validation of the Limulus Amebocyte
Lysate Test as an End Product
Endotoxin Test for Medical Devices
Test Dates: 1/17/89 - 2/28/89
Study Director: Donna Ventura
Purpose of
the Study: The purpose of this study was to demonstrate that
the LAL Test was an acceptable method to evaluate
PETG Bottles for the presence of gram-negative
bacterial endotoxin contamination and that it can
be used for product release.
STS Test Nos. T89-634, 635, 636 Page 4
Test Article: A. The following three lots of the test product
were submitted by Nalge Company for LAL
Testing and inhibition and enhancement
te st i ng :
1. 125 ml capacity PETG Bottles, Lot No.
257019D8
2. 500 ml capacity PETG Bottles, Lot No.
074250D8
3. 1000 ml capacity PETG Bottles, Lot No.
551636C8
Test Description: The Limulus Amebocyte Lysate (LAL) Test is based
on the property of the blood clotting action of
the horseshoe crab Limulus polyphemus. In the
presence of pyrogens, the lysate exhibits protein
coagulation. Extracts of the test articles are
prepared at 37C for a minimum of 30 minutes.
Lysate is then added to an aliquot of each extract
in a test tube and the resulting preparation is
incubated for 60
+
1 minute at 37 t 1C. The test
tube is inverted carefully through
180 and the
presence or absence of a clot is noted. Negative
controls, inhibition/enhancement samples and
positive controls are prepared and tested in the
same manner. This test is preferred because it is
less expensive, simple to perform, and more
quantitative than the USP Rabbit Pyrogen Test.
A USP In Vivo Pyrogen Test was also conducted, in
parallel, on each lot of the test article. These
extracts were prepared by filling ten samples of
the product with 400 ml of sterile, pyrogen-free
0.9J sodium chloride solution. The extract was
injected intravenously into the marginal ear vein
of each of three (3) rabbits at a dose of 10
ml /kg. Once an hour for three (3) hours, the body
temperature of each rabbit was determined. The
Individual maximum temperature rise and combined
maximum temperature rise was calculated.
Materials: A. Limulus Amebocyte Lysate
- PyrotellR:
obtained from Associates of Cape Cod, Inc.,
Woods Hole, MA, 02543. US License No. 700.
Lot No. 99-09-354 with a stated label
sensitivity of 0.25 EU/ml.
B. Sterile, Pyrogen-Free Water: prepared at
STS, was the extraction medium for the LAL
Validation Samples. Lot No. 021589-1, Exp.
3/15/89.
STS Test Nos. T89-634, 635, 636 Page 5
C Sterile, Pyroqen-Free 0.9% Sodium Chloride
Solution: prepared at STS, was the
extraction medium for the USP In Vivo
Pyrogen Samples. Lot No. 010589-1, Exp.
2/5/89 and 010689-1, Exp. 2/6/89.
Control Materials: A. Positive Control: Control Standard Endotoxin
(CSE) obtained from Associates of Cape Cod,
Inc., Woods Hole, MA 02543 (Lot No. 41)
used for LAL testing.
B. Negative Control : Sterile, pyrogen-free
distilled water was used for negative
control, for reconstituting Endotoxin
Standard and LAL, and for preparing the
appropriate dilutions in the standard curve.
-
*
Procedure: A. Extract Preparations:
Each lot of PETG Bottles was extracted for
testing. Each of ten (10) bottles per lot
was filled with 40 ml of water or saline.
Each PETG Bottle was capped, agitated, and
placed in a 37c incubator for 30 minutes.
After extraction, each bottle was agitated
again and the eluate was pooled into a
sterile, non-pyrogenic glass screw cap
bottle. Each eluate was used in the LAL
test or rabbit pyrogen test immediately
following preparation.
B. Limulus Amebocyte Lysate (LAL) Test:
The LAL test was conducted according to the
manufacturer's (Associates of Cape Cod,
Inc.) instructions provided with the LAL
test vials, by a technician trained and
certified for performing LAL tests.
Each LAL product eluate was evaluated, in
duplicate, for the presence of gram-negative
bacterial endotoxins with the LAL reagent
(PyrotellR, stated label sensitivity: 0.25
EU/ml). After the standard one hour
incubation at 370C, each tube was slowly and
carefully inverted 180 to observe for gel
formation. A positive LAL test 1s indicated
by the presence of a gel which remains
intact when the test vial is inverted.
STS Test Nos. T89-634, 635, 636 Page 6
In order to demonstrate the sensitivity and
reproducibility of the LAL test, a series of
endotoxin concentrations bracketing the
stated end-point sensitivity of the lysate
(0.25 EU/ml ) were also run, in duplicate,
with the product eluate LAL test. This
endotoxin series was prepared by making two
fold dilutions, using pyrogen-free distil
lee1
water, of a freshly prepared Escherichia
coli endotoxin standard (Control Standard
Endotoxin, (CSE) - Associates of Cape Cod,
Inc.). These known concentrations of
endotoxin, ranging from 0.5 EU/ml to 0.06
EU/ml, were then evaluated with the LAL test
vials to determine the endpoint sensitivity
of the test vials.
A second endotoxin series of
"spiked"
product eluate was also set up, and run in
parallel with the standard endotoxin series,
in order to rule out any inhibition, or
enhancement, of the lysate gel formation by
impurities 1n the product eluate. This
"spiked"
product eluate series was prepared
by adding known concentrations of the
freshly prepared standard Escherichia coli
endotoxin to the product eluate. The same
twofold dilution series, ranging from 0.5
EU/ml to 0.06 EU/ml , was set up with the
product eluate being used to make the
dilutions Instead of the pyrogen-free





series was then evaluated, in duplicate,
with the LAL test vials. Agreement between
the test results of this series and the
standard endotoxin series would indicate the
product eluate does not Interfere with the
lysate reaction. Endpoints between the
"spiked"
series and the standard series
cannot differ by more than plus or minus one
twofold dilution.
Finally, a negative control was run, in
duplicate with every product eluate LAL
test. Sterile pyrogen-free distilled water
was used as the negative control and
evaluated with the LAL test vials.
STS Test Nos. T89-634, 635, 636 Page 7
C. USP In Vivo Pyrogen Test:
A USP In Vivo Pyrogen test was also
performed on each lot of the test sample to
establish the sensitivity and
reproducibility of testing using the rabbit
colony.
The test involved measuring the rise in
temperature of 3 rabbits (per test sample)
following the Intravenous injection of the
test solution. Injection was through the
ear vein of each of three rabbits at 10 ml
of the test solution per kg of body weight.
The rabbit's temperatures were recorded at
1, 2, and 3 hour intervals subsequent to the
injection. Any temperature decrease was
considered as a zero rise. If no rabbit
showed an individual rise in temperature of
0.6C or more above its respective control
temperature and if the sum of the three
individual maximum temperature rises did not
exceed 1.40OC, the product met the
requirements for the absence of pyrogens.
The USP In Vivo Pyrogen Test was conducted
in a separate area designated soley for
pyrogen testing and was kept free from
disturbances likely to excite the rabbits in
study.
Resul ts : The standard endotoxin series which were run with
each LAL test, and bracketed the stated label
sensitivity of the LAL test vials, clearly
demonstrate the consistent sensitivity and
reproducibility of the LAL test.




which were performed on each eluate in parallel
with the standard endotoxin series, demonstrate
there 1s no inhibition or enhancement of the
lysate reaction caused by materials in the product
eluates. For each lot of product, there was no
significant difference between the LAL results




All sample extracts for the USP Rabbit Pyrogen
Test met USP requirements (Tables II - V) .
Individual maximum temperature rise was less than
0.60C. Combined maximum temperature rise was
less than 1.2C. The results are well within test
limits of 0.60C and 1.40C respectively.
STS Test Nos. T89-634, 635, 636 Page 3
Conclusion(s) : 1. The results of the tests conducted on PETG
Bottles indicate that the LAL test is a
reliable and valid test for evaluating this




Each USP Rabbit Pyrogen Test met
requirements.
USP
The results of this study Indicate that the
LAL test, performed with a standard
endotoxin series and negative control, is an
appropriate method for evaluating Nalge PETG
Bottles for pyrogenic ity and product
release.
Quality Assurance: The Quality Assurance Unit conducted inspections:





A signed statement released by
Assurance Unit is included with this





Lab test data, protocols, Standard Operating
Procedures, and final reports pertinent to this
study are on file in the archives at Sterilization
Technical Services, Inc., 7500 West Henrietta
Road, Rush, New York, 14543, and may be accessed
upon request.
Draft Guideline for Validation of the Limulus
Amebocyte Lysate Test as an End-Product Test for
Human and Animal Parenteral Drugs, Biological












STS Test Nos. T89-634, 635, 636 Page 9
TABLE I
Suanary of LAL Sensitivity,
Inhibition and Product Eluate Test
and USP InVivo Pyrogen Test Results
PETG BOTTLES
Test


















NOTE: The endpoint obtained here is within manufacturer's acceptable
limits.
* Lot No. 257019D8, T89-634
** Lot No. 074250D8, T89-635
*** Lot No. 551636C8, T89-636
STS Test Nos. T89-634, 635, 636 Page 10
TABLE I (Cont'd.)
Simary of LAL Sensitivity,
Inhibition and Product Eluate Test
and USP InVivo Pyrogen Test Results
PETG BOTTLES
Jest No.








4. LAL Test Negative Control
5. USP In Vivo Pyrogen Test
* Lot No. 257019D8, T89-634
** Lot No. 074250D8, T89-635


















































80216 39.69 12:06 0.00
80217 39.47 12:08 39.24 0.00

































80281 39.31 12:12 0.05
80284 39.64 12:14 39.35 0.00





Combined Maximum Temperature Rise (3 Rabbits)* 0.05C
* Test Limits:
1. Individual Wax Temp Rise (IMTR)
0.6oc/rabbit: None of the 3 rabbits
or only 3 of 8 rabbits may exceed limit
2. Combined Max Temp Rise
1.1oc/3 rabbits or
3.7C/8 rabbits
TS Test Nos. T89-634, 635, 636 Page 12
TABLE IV
Animal Weight Dose





















80422 3.77 37.7 39.63 12:20 39.38 0.00





Combined Maximum Temperature Rise (3 Rabbits)* 0.11c'C
* Test Limits:
1. Individual Max Temp Rise (IMTR) 2. Combined Max Temp Rise
0.6C/rabbit: None of the 3 rabbits 1.4C/3 rabbits or





V 7500 West Henrietta Rd. P.O. Box 349 Bush. New Yortc 14543 (716)533-1672
QUALITY ASSURANCE COMPLIANCE REPORT
The Quality Assurance Unit has completed Us audit.of:
Study HuHer/^./^.fiD/ *W'HhdAa^ Cl(\LP-lWl-M, h,r; /ULU U;
'J \ l\ i \l
Study Title: l_A L- \lfj iJjV^V
Test Report Number: "T$9- k < .3 ^ J^
There were no deviations from standard operating procedures or
protocols. This study passes the Quality Assurance Audit and 1s In
compliance with G.L.P. Regulations.
Phases(s) Inspected Audit Date
)MM nlfVL'ut 3/iiin
Quality Assurance: ijU/t (l/\JAJU- Date: 3klM
QA Document #600.3 MISC:F:103
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MOISTURE DATA (TABLE 7)
All vials were stored under 37C/85%RH. Two vials of
each configuration (with one exception) were randomly
selected from an environmental chamber. These were tested
using the Karl Fischer method of water determination with an
acceptable limit of 8.0% to 11.0%. The test procedure used
was direct titration (Method 1A).60 Irradiated glass at 3










PETG INITIAL 6.2% 11.0% 11.2% 9.5%
PETG 1 MONTH 13.2% 13.0% N/A 13.1%
PETG 3 MONTH 13.4% 15.7% N/A 14.6%
PETG(1 Mrad) INITIAL 10.3% 10.4% N/A 10.4%
PETG(1 Mrad) 1 MONTH 13.3% 13.3% N/A 13.3%
PETG(1 Mrad) 3 MONTH 15.4% 15.0% N/A 15.2%
GLASS INITIAL 9.4% 9.3% N/A 9.4%
GLASS 1 MONTH 9.6% 9.7% N/A 9.7%
GLASS 3 MONTH 8.9% 8.7% N/A 8.8%
GLASS (1 Mrad) INITIAL 8.7% 8.5% N/A 8.6%
GLASS (1 Mrad) 1 MONTH 8.4% 8.5% N/A 8.5%
60United States Pharmacopoeial Convention, United States
Pharmacopoeia XXII /National Formulary XVII, (Rockville: USP
Con., INC. 1990), 1619-1621.
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